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Abstract
Technological advances in imaging and radiotherapy have led to significant improvement
in the survival rate of breast cancer patients. However, a larger proportion of patients are
now exhibiting the less understood, latent effects of incidental cardiac irradiation that
occurs during left-sided breast radiotherapy. Here, we examine the utility of fourdimensional computed tomography (4D-CT) for the accurate assessment of cardiac dose;
and a hybrid positron emission tomography (PET) magnetic resonance imaging (MRI)
system to longitudinally study radiation-induced cardiac effects in a canine model.
Using 4D-CT and deformable dose accumulation, we assessed the variation caused by
breathing motion in the estimated dose to the heart, left-ventricle, and left anterior
descending artery (LAD) of left-sided breast cancer patients. The LAD showed
substantial variation in dose due to breathing. In light of this, we suggest the use of 4DCT and dose accumulation for future clinical studies looking at the relationship between
LAD dose and cardiac toxicity.
Although symptoms of cardiac dysfunction may not manifest clinically for 10-15 years
post radiation, PET-MRI can potentially identify earlier changes in cardiac inflammation
and perfusion that are typically asymptomatic. Using PET-MRI, the progression of
radiation-induced cardiac toxicity was assessed in a large animal model. Five canines
were imaged using 13N-ammonia and 18F-fluorodeoxyglucose (FDG) PET-MRI to assess
changes in myocardial perfusion and inflammation, respectively. All subjects were
imaged at baseline, 1 week, 4 weeks, 3 months, 6 months, and 12 months after focused
cardiac irradiation. To the best of our knowledge PET has not been previously used to
assess cardiac perfusion following irradiation.
The delivered dose to the heart, left ventricle, LAD, and left circumflex artery were
comparable to what has been observed during breast radiotherapy. Relative to baseline, a
transient increase in myocardial perfusion was observed followed by a gradual return to
baseline. However, a persistent increase in FDG uptake was observed throughout the
entire left ventricle, including both irradiated and less-irradiated portions of the heart.
ii

In light of these findings, we suggest the use of this imaging approach for future human
studies to assess mitigation strategies aimed at minimizing cardiac exposure and longterm toxicity subsequent to left-sided breast irradiation.

Keywords
Radiotherapy, breast cancer, radiation-induced toxicity, cardiac imaging, respiratory
motion, four dimensional computed tomography (4D-CT), positron emission tomography
(PET), perfusion, inflammation, hybrid imaging.
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Introduction

This thesis deals with an important and prognostically significant side-effect of breast
cancer treatment, specifically the cardiac effects on perfusion and inflammation of
radiation therapy. We begin with an overview of radiation therapy for cancer treatment
followed by a summary of the relevant literature on the topic of radiation induced cardiac
toxicity. Brief explanations are provided with regards to the techniques employed to
assess these effects in subsequent chapters. This chapter is concluded by highlighting the
gaps in knowledge, relevant problems/questions to the area of study, and the
hypothesis/aims of the thesis.

1.1 Radiation therapy for the treatment of cancer
In 2015, the Canadian Cancer Society reported approximately 80,000 Canadian deaths
due to cancer. Although this is a very sobering statistic, the significant progress made in
the last quarter century in diagnosing, understanding, and treating this disease is
encouraging. Technological advances in medical imaging systems(1) have improved the
ability to diagnose, plan treatments, and monitor response/recurrence in virtually every
cancer type. Identification of the exact location of cancer sites, even for moving tumours
situated in the lungs, is now possible and routine clinical practice.
After diagnosis, cancer is typically treated through surgery, chemotherapy, and/or
radiation therapy. Although this thesis provides less emphasis on surgery and
chemotherapy, their integral role in the treatment of cancer should not be underestimated.
Approximately two thirds of cancer patients will be treated with radiation (2). Radiation
therapy can be delivered using two approaches 1) external beam radiotherapy, where a
radioactive source originates outside the patient or 2) brachytherapy, where the
radioactive source is implanted within the patient.Nearly 90% of patients treated with
radiation, receive external beam radiotherapy(2), delivered via a linear accelerator
(commonly referred to as a LINAC).
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1.1.1

Linear Accelerators (LINACs) – General Overview

The linear accelerator (LINAC) is used to accelerate charged particles (typically 4-25
MeV electrons) that can be used to treat superficial tumours. Deeper lesions can also be
treated using non-charged particles created after the kinetic energy of the electrons is
converted into x-rays. Figure 1-1 is adapted from Podgorsak, et al(3) and highlights the
major components of a typical LINAC.

Figure 1-1: A schematic of a typical isocentric medical linear accelerator (panel A)
and a photograph of a commercial unit (Varian Medical Systems; panel B). adapted
from Podgorsak, 2005 (3)
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In general, the forming of the treatment beam of radiation begins with the genesis of
“free” electrons. Electrons are liberated from a cathode through a process of thermionic
emission and accelerated through a perforated anode into the next major component of
the LINAC, the accelerating waveguide. Inside the accelerating waveguide, the injected
electrons interact with high powered radiofrequency fields. In the waveguide electrons
can reach velocities greater than 99.9% of the speed of light. These high-energy electrons
are then steered, through the use of magnets, towards an x-ray target located in the head
of the LINAC. The energy lost by the electrons during the collisions with the target
produce high energy x-rays for treatment. Alternatively, the target can be retracted and
electrons are allowed to exit the LINAC for electron beam therapy. The above is a very
brief overview with regards to the inner workings of the typical medical LINAC, the
following references provide a more detailed description(3, 4).
The delivery of radiation therapy via LINACs has been significantly improved over the
last 25 years and continues to improve rapidly (5, 6). Medical LINACs in both academic
and smaller non-academic cancer centres now have the ability to shape/vary the intensity
of the radiation beam and provide on board imaging. Figure 1-2 illustrates the progressive
improvements in our ability to conform radiation doses to a tumour. The techniques
available to achieve this conformity have been collectively termed intensity modulated
radiation therapy (IMRT) and have been made possible through the addition of computercontrolled multi-leaf collimator systems (MLC) in the head of the LINAC. The positions
of the MLCs needed to achieve a desired dose distribution is obtained during the
radiation treatment planning process through an inverse optimization algorithm(7).
On board, fluoroscopic x-ray imaging and cone-beam computed tomography(8) systems
have been primarily used to improve the ability to reproducibly set up patients on the
treatment couch. Since RT is typically multi-fractionated, the day to day reproducibility
is paramount for successful treatment. Through the use of on-board imaging, set-up
uncertainty is now ≤ 5mm (9). Additionally, on board imaging can potentially provide
more personalized treatment strategies, commonly referred to as adaptive radiation
therapy(10). The goal of adaptive radiation therapy is to quickly and efficiently re-plan
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and optimize each patient’s radiation treatment in response to volumetric and/or
functional changes in their anatomy observed via imaging during the course of treatment.

Figure 1-2: Prostate cancer radiotherapy 1935–2010. Prostate cancer irradiation is a
good example of the improvement of radiotherapy technology over the past decades.
By increasing the beam energy and the precision of the targeting, it was possible to
escalate the dose to the prostate without exceeding the tolerance dose of healthy
tissues; allowing the move from palliative irradiation to curative treatment.
Abbreviations: 3D-CRT, 3D conformal radiotherapy; IMRT, intensity modulated
radiotherapy; RT, radiotherapy. Reprinted with permission from Nature Review
Clinical Oncology; Thariat J, et al. Nat. Rev. Clin. Oncol. 2012;10:52–60.
The ultimate metric for assessing the effectiveness of these advances, is how they
translate to improvements in the overall survival of cancer patients. One of the most
encouraging examples can be drawn from the significant improvement in the survival rate
of breast cancer patients (11) (see Figure 1-3). The five-year, 10-year, and 15-year
survival rate for breast cancer is now 89%, 83%, and 78% respectively (11, 12). In
addition to the improved conformity of radiotherapy delivery, this cohort of patients has
also benefited from technological advances in medical imaging which have led to earlier
diagnosis. An important caveat when interpreting these improvements in survival rates is
the presence of known bias (~overestimation of 1.25 years) (13). This lead bias is due to
the fact that breast cancer patients who have been diagnosed earlier will naturally live
longer after diagnosis. The improved survival consequently leads to an increase in the
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less understood long-term side-effects of cancer treatment. One clinically significant and
heavily debated side effect of breast, lung, and esophageal cancer treatment is radiationinduced cardiac toxicity (RICT)(14). The over-arching focus of this thesis is the negative
effects of breast cancer radiotherapy on the heart.

Figure 1-3: Five year survival percentage following breast cancer diagnosis from
1975-2012. Obtained from Howlader N, et al. Surveillance, Epidemiology, and End
Results Cancer Statistics Review, 1975-2011. Natl. Cancer Inst. 2014.

1.2 Left-sided breast cancer radiotherapy
The five year survival statistic of Canadian breast cancer patients is above 80%; however,
breast cancer still accounts for nearly 25% of the total yearly female cancer
mortalities(15). Although this may seem counter-intuitive, it is explained by the large
incidence rate of breast cancer; statistically, 1 in 4 females will be diagnosed with breast
cancer in their lifetime(15). Although patients are responding well to treatment, the large
volume of diagnosed patients leads to a significant number of mortalities even with cure
rates at ~80%.
Breast cancer is typically treated with a combination of surgery, chemotherapy, and/or
radiation therapy. The radiotherapy for breast cancer is most commonly delivered using a
medical LINAC. The primary goal for breast cancer radiotherapy planning is to deliver
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the clinically prescribed radiation dose (~50 Gy) to the entire breast or if following
mastectomy, the entire chest wall. The radiation is typically delivered using two
sequential radiation beams oriented such that they are tangential to the chest wall and
opposed to each other, commonly referred to as tangential parallel-opposed or POP
arrangement (see Figure 1-4). A secondary goal of radiotherapy planning is to avoid
irradiating the surrounding healthy organs. However, this cannot always be achieved
when organs are in close proximity to the treatment site.

Figure 1-4: A transverse computed tomography (CT) image of a left-sided breast
cancer patient. The radiation dose distribution from treatment is overlaid onto the
left breast. The entire heart, left ventricle only, and left anterior descending artery
are contoured in magenta, yellow, and blue respectively. The typical orientation of
the tangential parallel opposed beam arrangement is indicated by the red arrows.
For left-sided breast cancer patients, the lung, heart, and major coronary arteries tend to
be co-irradiated due their close proximity to the anterior chest wall (Figure 1-4). A
recently published systematic review reported the mean dose to the hearts of left-sided
breast cancer patients to be 5.4 Gy and as high as ~8Gy if the treatment includes the
internal mammary chain(16). Darby et al reported that the rate of a major coronary event
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increased linearly by 7.4% per Gy with no apparent threshold below which there is no
risk(17). The relative risk of cardiac toxicity due to radiation is also considerably
amplified by the presence of pre-existent risk factors such as diabetes, smoking, and
chemotherapy (17). Comparisons between left-sided and right sided breast cancer
patients in terms of cardiac toxicity are essential in understanding the effects of radiation
isolated from the concomitant factors such as chemotherapy and more conventional
cardiac risk factors (see Figure 1-5). Correa et al, reported clinically significant heart
disease developed in 59% of left-sided breast cancer patients compared to only 8% in
right-sided breast cancer patients(18), 70% of which were in the left anterior descending
artery (LAD) territory (predominately in the middle and distal segments).

Figure 1-5: A comparison of left and right sided breast cancer patients regarding
the presence of clinically significant coronary artery disease 10 -15 years following
radiotherapy treatment. Proportions are obtained from Canadian Cancer Statistics,
2015 and Correa CR, et al. J. Clin. Oncol. 2007(18).
The evidence for the harmful effects of radiation on the heart is supported by numerous
studies looking at clinical endpoints such as cardiac mortality and/or myocardial
infarction in cancer patients and atomic bomb survivors(14, 16, 17, 19–22). Irradiation of
the heart can result in a myriad of known cardiac and vascular pathologies; however, the
underlying mechanisms and progression are not yet well understood. The future
management and prevention of radiation-induced cardiac toxicity will require close
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collaboration between the departments of oncology and cardiology. As a result, a new
‘hybrid’ discipline, termed cardio-oncology is beginning to emerge(23).

1.3 Radiation induced cardiac toxicity: Clinical Endpoints
There are several known clinically significant side-effects to cardiac irradiation. A
detailed review of the literature is provided by Gagliardi, et al (14). The most common
clinical endpoints that have been associated with cardiac irradiation are; pericarditis,
myocardial infarction, valvular disease, congestive heart failure, and coronary artery
disease. Some of these endpoints also occur in a high proportion of older patients without
cardiac irradiation, making conclusions difficult without the use of non-irradiated control
groups. In general, trials comparing irradiated and non-irradiated subjects for the above
endpoints have shown relative risks ranging from 1.2 to 3.5 for those treated with
radiation (14).

1.3.1

Acute and chronic pericarditis

Pericarditis is inflammation within the thin membrane that encloses the heart, referred to
as the pericardium. Patients with pericarditis often suffer from chest pain. Generally, the
disease will clear up naturally within a few days to weeks, once the inflammatory process
resolves, although the length of the active process will vary depending on the inciting
stimulus for inflammation. In rare cases surgery is needed to prevent complications.
A longitudinal analysis report on the incidence of pericarditis in women treated with
radiotherapy for breast cancer(22) showed a pericarditis relative incidence ratio of 1.61
between the left-sided vs right-sided breast cancer patients. It should be noted that
patients included in the above study were treated in the late 70’s and followed for up to
30 years post-radiotherapy. Current methods for breast irradiation have improved
significantly and as a result pericarditis is now an uncommon side effect of breast cancer
radiotherapy. Acute pericarditis typically develops a few weeks following high exposure
levels to the heart (≥ 36 Gy). These exposure levels are not typically observed in the
breast cancer population but can sometimes occur for patients with tumours located
within the mediastinum.
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1.3.2

Myocardial infarction

Myocardial infarction or more commonly called a heart attack refers to damage or death
to a portion of the myocardium. Myocardial damage and/or death are usually the result of
an occluded coronary artery preventing the flow of blood to the myocardium.
The incidence ratio for acute myocardial infarction between left-sided and right-sided
breast cancer patients is reported as 1.22, with 95% confidence interval between 1.061.42(22). As previously mentioned these incidence ratios may be inflated due to higher
exposure levels to the heart observed using older treatment technology. Literature using
more modern treatment methods are rare due to the latency (>15 years) for myocardial
infarction to develop following irradiation. A study of >14,000 long-term childhood
cancer survivors receiving radiotherapy (heart doses > 5Gy) have shown a hazard rate of
2.4 for myocardial infarction compared to matched non-irradiated cancer survivors(24).

1.3.3

Valvular Disease

Valvular disease following cardiac irradiation can lead to valve stenosis and/or
regurgitation. Valve stenosis refers to a heart valve that does not fully open. This leads to
increased load on the heart to pump blood through the narrow opening of the stenosed
valve. Valve regurgitation refers to “leaky” valves that do not close properly causing
additional strain on the heart to pump blood.
An incidence ratio 1.54 for valvular disease between left-sided and right-sided breast
cancer patients has been previously reported(22). Radiation related valvular abnormalities
are more commonly observed in Hodgkin’s lymphoma survivors(25) than in breast
cancer survivors as Hodgkin’s patients will often receive high dose mediastinal radiation.
Valvular disease can be expected following heart doses >25 Gy(26).

1.3.4

Congestive heart failure

Damage to the myocardium most commonly caused by myocardial infarction can lead to
reduced ability for the heart to contract/relax; this is referred to as congestive heart
failure.
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An increased incidence of congestive heart failure (incidence ratio = 7.4) has been
observed following cardiac irradiation during the treatment of Hodgkin’s lymphoma(27).
Increased risk of congestive heart failure following breast cancer radiotherapy has only
been shown for early treatment techniques between 1970 and 1986(28). Heart doses
<7Gy do not appear to result in an increased risk of congestive heart failure(29).

1.3.5

Coronary artery disease

Coronary artery disease refers to significant blockage of the coronary arteries leading to a
disruption in blood flow to the heart. The source of the blockage is typically referred to as
an atherosclerotic plaque. The atherosclerotic process is still not fully understood, Libby,
et al provide a comprehensive review of the topic(30).
Harris, et al, showed that left-sided breast cancer patients treated between 1977-1994 had
a significantly greater risk of coronary artery disease than right-sided patients(31).
Coronary artery disease is believed to be the predominant clinical endpoint following
cardiac irradiation(32). Experimental studies provide evidence for two interesting
hypotheses; 1) radiation causes an acceleration of the atherosclerotic process(33) and, 2)
the resulting atherosclerotic plaques are of a phenotype that is more prone to rupture(33).
The most common theme in the clinical end-points discussed above is that the
progression towards them is slow (> 10 years following irradiation). In order to study the
progression of radiation induced cardiac toxicity in a timelier manner, sub-clinical endpoints in asymptomatic patients and/or animal models need to be used. In addition to
improved understanding of the disease progression, identifying predictive sub-clinical
endpoints may open a window for early interventions that can protect breast cancer
patients from the life threatening side effects discussed above.

1.4 Radiation induced cardiac toxicity: Subclinical
Endpoints
More subtle changes will surely precede the life threatening clinical endpoints mentioned
in the previous section. In this thesis, subclinical endpoints refer to these subtle changes if
they can be detected non-invasively in humans. Experimental studies in animal models

11

play a pivotal role in identifying subclinical endpoints that can be used to monitor and
then potentially augment radiation treatment to reduce the risk of radiation induced
cardiac toxicity.

We begin with a brief introduction of the interaction of ionizing

radiation on biological tissue; this area of study is commonly referred to as radiobiology.
Our focus is not to provide a comprehensive review of radiobiology, but rather we aim to
highlight areas most relevant to radiation induced cardiac toxicity. A more complete
review of radiobiology is provided by Hall and Giaccia(34).

1.4.1

Radiobiology primer

The study of the effects of ionizing radiation on living organisms began almost
immediately after Röntgen’s discovery of the x-ray in 1895. The biological effects
observed following irradiation are primarily a result of DNA damage. Ionizing radiation
can either directly or indirectly (through the genesis of highly reactive oxygen species)
cause breaks in the DNA. Consequently, the cell’s natural repair mechanisms respond to
the damaged DNA leading to 1 of 3 potential outcomes: 1) the cell successfully repairs
the DNA; 2) the cell cannot repair the damage and responds by initiating apoptosis; 3) the
cell incorrectly repairs the DNA resulting in a mutated living cell that may have an
altered role within the body. This cascade provided the foundation for the fundamental
law of radiobiology, “law of Bergonie and Tribondeau”(35). In general, the law
designates organs/cells with low mitotic vs high mitotic activity to be considered
radiation-resistant and radiation-sensitive, respectively. Additionally, the law states that
radiation sensitivity is inversely proportional to the cell’s differentiation status. The heart
and the blood vessels have been shown to be composed of highly differentiated cells with
low mitotic activity. Annual cardiomyocyte turnover is less than 1% (36) in comparison
to the intestines and lungs which have 100% turnover in just a few days and months,
respectively (37). This is counter-intuitive considering the vast amount of
epidemiological evidence presented previously with regards to the heart’s apparent
sensitivity to radiation, although the clinical effects are generally not observed for several
years. As such, the radiobiology of the heart and vasculature follow a less common and
less understood cascade towards radiation injury.
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1.4.2

Radiobiology of the vasculature

The vasculature, specifically the endothelial cells lining the lumen of blood vessels are
considered highly differentiated cells with low mitotic activity. Evidence exists that
radiation injury to cells does not just follow the typical DNA repair cascade but may also
originate at the cell membrane. Radiation has been shown in vitro and in vivo to initiate
the hydrolysis of the cell membrane resulting in cell signaling of apoptosis(38). The same
apoptotic signal mediator has also been observed in the heart during myocardial
ischemia(39). The effects of radiation on the cellular membrane often results in
alterations to the attachment, morphology, and continuity of the endothelial cell
monolayer lining the vasculature(40).
The majority of these alterations result in potential subclinical endpoints such as
increased vascular permeability, fibrosis, and/or inflammation(41, 42). Changes in
vascular permeability of the microcirculation can and has been previously assessed in
breast cancer patients through the use of perfusion imaging. However, results from
human studies using single photon emission computed tomography (SPECT) following
breast cancer radiotherapy are inconclusive. Zellars et al, reports regions of increased and
separate regions of decreased perfusion(43). Other studies have shown reductions in
cardiac perfusion following radiotherapy in ~50% of left sided breast cancer patients(44,
45). Chung et al, did not observe any perfusion defects 6 months following left-sided
breast radiotherapy(46). Lawrence et al reported that the incidence of new perfusion
defects 6, 12, 18, and 24 months after radiotherapy was 27%, 29%, 38%, and 42%,
respectively(47). Potential technical reasons for disagreement are presented in subsequent
sections.
Irradiation of the vascular endothelium has been shown to activate transcription factors
that lead to pro-inflammatory, pro-coagulation, and leukocyte adhesion (33, 48–51).
These studies in mice have shown that focal cardiac irradiation leads to an acceleration of
the atherosclerotic process with plaque phenotypes prone to rupture. Gabriels et al, have
shown that high doses to the heart (>16 Gy) induce a cell signaling cascade towards
fibrosis, whereas low doses (~2 Gy) trigger an initial “survival response”, encouraging
cellular growth, development, and proliferation(49). In mice, increases in endothelial cell
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surface markers related to inflammation and proliferation can remain elevated up to 20
weeks post irradiation (49, 52). Through the use of nuclear imaging, myocardial fibrosis
and inflammation can also be assessed non-invasively in breast cancer patients following
radiotherapy. However, to the best of our knowledge it has not yet been attempted.
In light of the findings above, macrovascular and microvascular functional imaging is a
logical target for monitoring the progression of radiation induced cardiac toxicity in
humans. Vascular imaging may also play a role in assessing the efficacy of advanced
radiation delivery strategies used to mitigate cardiac toxicity.

1.5 Advanced radiation delivery strategies for mitigation
1.5.1

Standard breast cancer radiotherapy

The commonly used setup prior to irradiation is as follows; breast cancer patients are
typically set-up in the supine position with arms extended above the head. A breast board
is used for patient immobilization. Radio-opaque markers are typically used to help
identify clinical boundaries of the targeted breast volume. The typical prescription dose is
50 Gy in 25 fractions. Beam energies are typically between 4 – 10 MV; however, mixed
beams, beams with higher energies, and local boosts can be used to ensure sufficient
target coverage and minimize the incidence of local recurrence.
The tangential parallel opposed technique for breast irradiation begins with a freebreathing computed tomography scan that is used for treatment simulation. Tangential
beams are used to target the breast volume and the beams are angled to minimize the
divergence of the beam into the heart. A recently published meta-analysis showed that the
mean heart dose using standard tangential fields can vary considerably (2.5 - 11.18
Gy)(53).
Additionally, intensity modulated radiation therapy (IMRT) can be used for treatment.
IMRT beams vary in intensity to produce non-uniform fluency, allowing for greater
conformity to target structures while reducing the dose to specified avoidance structures.
For more degrees of freedom, IMRT can also be delivered in an arc, either with
volumetric modulated arc therapy (VMAT) or with Tomotherapy. The previously
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mentioned meta-analysis showed that mean heart doses using IMRT can also vary
considerably (1.1 - 13.4 Gy)(53).
Several modifications and alternatives to the traditional tangential parallel opposed beam
arrangement have been proposed to reduce the amount of heart exposure during breast
radiotherapy. The modifications primarily employ respiratory motion management
strategies to minimize heart dose during radiotherapy. Additional, proposed alternatives
to the standard treatment are brachytherapy, proton radiotherapy, and treating patients in
the prone position. Currently there has not been any consensus regarding the “best
approach”. The reasons for the lack of consensus and other key findings from the
published literature are summarized below.

1.5.2

Respiratory motion management during radiotherapy

Modern day LINACs can be automatically triggered such that the beam of radiation is
only delivered at specific portions of a patients breathing cycle. The three most
commonly used respiratory triggers are abdominal strain gauges, video tracking of an
external marker, and spirometry(54). The abdominal strain gauge, commonly referred to
as the bellows system (Philips Medical Systems, Cleveland, USA) is tightly fastened to a
patient’s abdomen, below the diaphragm. A patient’s respiratory trace is obtained by
measuring changes in the pressure exerted by the breathing induced motion of diaphragm
against the bellows system. Another approach is video monitoring of an external marker
secured to the patient’s abdomen. This system is commercially referred to as the real-time
position management system (Varian RPM system, Varian Medical Systems, Palo Alto,
USA). The motion of the external marker follows the same principle described for the
bellows device. The third approach uses a spirometer to obtain a respiratory signal by
measuring the volume of air entering and exiting the lungs. This system is commonly
referred to as active breathing control (ABC). These systems are commonly used for
triggering the LINAC to specific parts of a patients breathing cycle. They are also used
to reduce respiratory motion artifacts in tomographic imaging, specifically for lung
cancer patients. It should be noted that these signals are only surrogates of internal organ
motion and require validation as deviations have been reported (55). The application of
these systems regarding reducing heart exposure during radiotherapy is principled in that
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the heart is typically furthest from the breast during the end of inspiration. By triggering
the beam on at the end of inspiration, the added separation between the breast and heart
leads to a significant reduction in cardiac exposure.

1.5.3

Inspiratory gating and breath-holds during left-sided breast
radiotherapy

The use of breath-holds during treatment, specifically deep-inspiration breath-holds have
been shown to significantly reduce the mean heart dose in breast cancer patients by 40%
(56). With regards to the deep inspiration breath-hold techniques, concern exists with
regards to compliance and inefficiency in terms of time needed to train patients prior to
treatment. In light of this, Korreman et al, proposed the use of inspiratory gating while
the patient is freely breathing to avoid the need for patient training (57). Their study has
shown that the dose reduction to the heart and LAD is not statistically different between
deep-inspiration breath-holds vs inspiratory gating during free-breathing. It should be
noted that both breath-hold and gated methods do not account for the contractile motion
of the heart itself. Wang, et al has shown that this motion may be negligible for the heart
but not for the LAD (58). To account for cardiac motion, their study suggests that
treatment plans should maintain at least a 5 mm margin between the posterior edge of the
radiation field and the LAD.
The use of gating and breath-holds consistently results in reduced mean heart dose;
however, a recent clinical trial unexpectedly reported a worsening in cardiac perfusion in
the apex of the left ventricular compared to standard treatment(43). The authors of the
study suggest that although the motion management approaches reduce mean heart dose,
they may cause a repositioning of the heart such that critical sub-structures such as the
LAD may receive higher doses.

Thus, although the mean heart dose is often cited, it

may not be an appropriate metric for the assessment of these treatment strategies. Several
studies suggest that doses to the LAD may be more appropriate (18, 59) for predicting
cardiac toxicity. Currently there is no clinical consensus as to a means of stratifying
patients most likely to benefit from gating/breath-hold treatments.
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1.5.4

Brachytherapy for the treatment of breast cancer

Brachytherapy refers to a type of radiation treatment in which a source of radiation is
placed near or within the area being treated. Brachytherapy has the benefit of being able
to deliver high doses of radiation with very rapid fall-off in dose to tissues not
immediately adjacent to the source. Placement of the radioactive sources is performed in
the operating room with the aid of image guidance. The sources are typically “afterloaded”, meaning that a catheter is first placed at the target position then the sources are
automatically advanced through the catheter and loaded into position. The dose
distribution for a given source can be altered by changing their positions within the target
and/or changing the duration they are loaded (referred to as dwell time). Several
brachytherapy approaches have been proposed for early stage breast cancer patients (60–
63); however, the most promising results are for the multi-catheter interstitial
brachytherapy approach(62, 63). In comparison to standard radiotherapy, brachytherapy
can significantly reduce both the maximum dose and the total volume of the heart that is
irradiated during treatment(62). More importantly, this reduction in dose to the heart can
be achieved without compromises in local control/rate recurrence at least 5-years post
treatment(63). The use of brachytherapy for the treatment of early stage breast cancer is
commonly referred to as accelerated partial breast irradiation. In addition to the reasons
mentioned above, accelerated partial breast irradiation is an attractive alternative to the
standard treatment since it can shorten the course of treatment from 3-7 weeks to 2-5
days. Unfortunately, this technique has only shown comparable control rates for early
stage breast cancer patients with no lymph node involvement (stages 0, I, and IIa) (63).
Accelerated partial breast irradiation can also be delivered intra-operatively (61);
however this approach was shown to result in higher proportion of recurrence then the
standard technique. Additionally, stereotactic external beam radiotherapy has been used
as an attractive alternative for the delivery of accelerated partial breast irradiation as this
approach is non-invasive and significantly easier to implement clinically (64). This
approach has shown comparable local control to the standard (1.5% recurrence at 5
years); however poor cosmetic outcomes are typically reported with external beam
radiotherapy.
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1.5.5

Breast cancer treatment in the prone position

Another proposed approach for reducing cardiac irradiation during breast cancer
treatment is to treat the patient lying prone on the treatment couch (65–67). With the
patient lying in the prone position, more separation can be achieved between the heart
and the breast. Kirby, et al has shown that significant reductions in dose to the LAD
(mean dose reduction ~6 Gy; max dose reduction ~30 Gy) can be achieved(66).
However, generally these reductions are only observed in patients with larger breast
volume (>1000 cm3). Furthermore, treatment in the prone position was shown to be
detrimental in women with smaller breast volume since in the prone position the
separation between the heart and the chest wall is reduced. Conversely, Lymberis, et al
reported that most women benefited from the prone treatment position regardless of
breast size; however, doses to the LAD were not reported in this study(65). Further study
is needed to provide guidelines for ensuring reproducible day to day patient setup prior to
widespread adoption in the clinic.

1.5.6

Breast cancer treatment using proton radiotherapy

External beam radiotherapy is typically carried out with LINACs that produce either xrays or electrons; however, there is considerable interest in the use of heavier particles
such as protons for breast cancer radiotherapy in order to reduce the dose to the heart(68–
71). Galland-Girodet et al, reported 0 Gy mean dose and only 4 Gy max dose to the heart
using protons for accelerated partial breast irradiation (72). Proton radiotherapy is
capable of reducing dose deposition to healthy tissues situated distal to the target due to
their superior dose deposition characteristics in comparison to photons and electrons.
However, similar to photon radiotherapy, high skin dose and poor cosmetic outcomes are
often reported (72). The radiotherapy comparative effectiveness trial (RADCOMP) has
been funded to compare the effectiveness of proton vs photon radiotherapy for breast
patients (NCT02603341). Identifying whether or not protons can reduce cardiac mortality
after breast cancer is one of the RADCOMP trial’s primary goals. Proton therapy is
largely limited by the considerable amount of capital needed to create a medical proton
accelerator. Thus only a few institutions have them for clinical use. Although upfront
capital costs are high, reported estimates of the cost per treatment using protons shows
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only a 5% increase in comparison to the cost of a 6 week course of standard tangential
whole breast irradiation(68).
Currently there is no consensus with regards to how a center should identify which leftsided breast cancer patients are most likely to benefit from these advanced techniques
which are generally more resource intensive and time consuming that the standard
treatment. Additionally, long-term assessment of these novel strategies is still needed.
Long-term follow-up studies are currently in place and are most ideal since radiation
induced cardiac toxicity is a latent side-effect (typically 10-15 years post radiation).
However, with the result from future studies pending, diagnostic and functional cardiac
imaging has been suggested to monitor the evolution and progression of radiation
induced cardiac toxicity at earlier time points(73, 74).

1.6 Advanced cardiac imaging of radiation-induced injury
The potential effects of radiation on the heart can be imaged non-invasively through
echocardiography, computed tomography (CT), nuclear tomographic imaging, and
magnetic resonance imaging (MRI), each with relative strengths in assessing different
parameters of radiation-induced injury. Their previous and potential role for studying
radiation-induced cardiac toxicity is discussed below.

1.6.1

Echocardiography

Echocardiography can produce both 2-dimensional and 3-dimensional images of the
heart. In general, images are produced after an ultrasonic pulse is emitted from an
ultrasonic transducer through the specimen to be imaged. Ultrasonic echoes produced at
the interfaces between different tissue types are acquired by the transducer and used for
image reconstruction. In addition to images, the Doppler Effect can be utilized to obtain
functional information such as blood flow and regional strain. Fenster, et al provides a
more detailed and technical review of ultrasound imaging(75).
Echocardiography has shown decreased myocardial systolic deformation (strain) in the
left sided breast cancer patients as early as 2 months and up to 14 months post
irradiation(76, 77). Regional changes were observed compared to baseline measures;
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however, they were not statistically correlated with regional dose. Unfortunately, the
authors did not provide a patho-physiological mechanism for the observed reduction in
myocardial strain. The overall clinical consequences of reductions in myocardial strain
due to irradiation require further investigation.

1.6.2

Computed Tomography (CT)

Computed tomography imaging can provide high resolution cardiac images (~ 1mm
isotropic voxels) and anatomic information such as the extent of coronary stenosis and
functional information such as regional myocardial perfusion. Additionally, CT images
can be used to accurately calculate doses from radiotherapy. CT based dose calculations
are possible because the image signal intensity is directly related to tissue electron
density (78). CT images are acquired by detecting the transmission of kilovoltage (kV)
photons as they pass through a sample. Rotating the photon source and detector around
the specimen gives multiple projections that can be later reconstructed into a 2dimensional (2D) image. A 3-dimensional (3D) volume can be obtained by longitudinally
advancing the couch of the CT scanner while acquiring projections, commonly referred
to as helical CT. Each set of projections is reconstructed into an image “slice” through
the sample. For those interested, Johns and Cunningham provide a more comprehensive
description of CT imaging (79).
Cardiac CT studies of radiation induced cardiac toxicity are limited to microCT studies in
mice(80) and Hodgkins survivors (81, 82). For left-sided breast cancer patients, the role
of CT has been primarily reserved for quantifying the delivered dose to the heart and the
LAD following standard and more advanced radiotherapy techniques (83, 84).
Calculating the dose to heart, left ventricle, and LAD from standard helical CT imaging is
challenging since this technique does not capture the motion of the heart or the LAD.
Standard helical CT scanners used for breast radiotherapy planning do not have the
temporal resolution to acquire artifact free, real-time images of internal organ motion due
to respiration. This also poses a major challenge for treating tumor sites subject to
respiratory motion such as the lung or liver. This problem is typically addressed through
the use of a longer duration helical CT scan in which the pitch of the couch is slowed
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such that multiple images can be acquired at the same slice position. Through the use of a
breathing motion surrogate, the images can be retrospectively sorted to specific portions
of the breathing cycle. This technique is commonly referred to as 4D-CT imaging(85,
86). However, 4D-CT is not part of the current standard of care for breast cancer patients
and only few studies have partially examined its utility for assessing cardiac dose
associated with breast radiotherapy (83, 84, 87, 88). The use of 4D-CT imaging also
allows for the estimation of dose distributions that have been “blurred/warped” in
accordance to the motion of the internal anatomy. This warping of dose is commonly
referred to as 4D dose accumulation (89). Unfortunately, adoption of 4D dose
accumulation in clinics today is primarily hindered by challenges associated with proper
validation of the accuracy of the dose deformation(90).
In comparison to all the other imaging modalities, CT is the most widely available and
extensively used in day to day cancer radiotherapy. Thus the emergence of functional
cardiac CT perfusion may have a key role in future radiation induced cardiac toxicity
trials(91). Quantitative cardiac CT perfusion has been recently validated using
microspheres in porcine model of myocardial infaction(92). In comparison to goldstandard measurement (microspheres), CT perfusion is strongly correlated with the goldstandard measurement (R = 0.81), however, the method tends to overestimate perfusion
by 20-25% due to beam hardening artifact caused by the contrast agent within the LV.

1.6.3

Nuclear tomographic imaging

Nuclear tomographic imaging has been used extensively to study cardiac pathology and
in the routine clinical management of cardiovascular disease (93). In general, nuclear
imaging is performed after a radio-isotope is injected into or inhaled by the patient. The
radio-isotopes used in nuclear imaging are commonly referred to as radio-tracers.
Different tracers tend to be specific to different biochemical pathways that occur within
the body. The emitted radio-activity from the tracers can be detected by the imaging
system after and/or during its distribution within the body. Tomographic image
reconstruction algorithms are used to convert the emitted signal from within the body into
images. The pixel intensity of the reconstructed images is proportional to the radio-tracer
concentration in that region. The two most commonly used nuclear imaging systems are
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single photon emission computed tomography (SPECT) and positron emission
tomography (PET). There are many differences between SPECT and PET imaging
systems, however, many of these differences are initially rooted in the fact that they use
different types of radio-isotopes. In SPECT, the radio-isotopes are gamma-emitters; in
PET, the radio-isotopes are positron emitters. A comprehensive description of these
techniques is provided by Cherry, et al (94). To date, the use of nuclear imaging for the
assessment of radiation-induced cardiac toxicity has been limited to SPECT myocardial
perfusion, ejection fraction, and multigated acquisition studies.

1.6.3.1

SPECT imaging of radiation-induced cardiac toxicity

SPECT myocardial perfusion imaging is typically performed using thallium (

201

Tl)

labelled or technetium (99mTc) labelled radio-tracers (95). Both of these tracers become
metabolically trapped within the myocardium and their distribution within the heart is
proportional to the regional myocardial blood flow. Thallium is an analog to potassium
and is actively transported into cells through the sodium potassium pump. Unlike

201

Tl,

99m

Tc does not have a natural biochemical affinity for the myocardium. For this reason,

99m

Tc is bound to a molecule with some cardiac affinity (typically sestamibi or

tetrofosmin). Sestamibi and tetrofosmin are positively charged molecules that enter the
intracellular space via passive transport and accumulate in the mitochondria of cardiac
cells(96).
Numerous studies have reported myocardial perfusion defects following left-sided breast
cancer radiotherapy(18, 43, 45–47, 59, 97–99). An often cited finding was the ability to
stratify patients most likely to present with perfusion defects by the volume of the heart
irradiated with 25 Gy or more (47). Marks et al, studied a cohort of 114 patients treated
between 1998 -2001. The patients were followed using SPECT perfusion imaging
between 6 to 24 months post radiotherapy. In this study, new perfusion defects occurred
in more than half of left-sided breast cancer patients with more than 5% of the heart
irradiated by 25 Gy or more(47). These defects were typically observed 1-2 years post
radiotherapy, however, in a smaller proportion of patients (< 30%), defects as early as 6
months post irradiation were observed. The perfusion defects tend to be isolated to
myocardial regions irradiated by at least 25 Gy. For left-sided breast cancer patients, this
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tends to be the area of the heart supplied by the LAD (59). Similar findings are echoed in
many of the other SPECT studies, however, not all studies observed cardiac perfusion
defects. Sioka et al, compared 28 left and 18 right sided breast cancer patient treated
between 1998 – 2010

using SPECT with a median follow-up of 40 months (45).

Although the study found a difference between age-matched controls vs breast cancer
patients, no differences were observed between left and right-sided patients. This lack of
difference may be attributed to the small number of patients in the comparison. A recent
study of 32 left-sided breast cancer patients with pre and 1 year follow-up SPECT, did
not show any significant differences in perfusion or ejection fraction (46). The
discrepancy between the findings from this study and the previous studies may be
attributed to the lower mean heart dose or the shorter follow-up (1 year, 2.8 Gy (46) vs 40
months, ~7.7 Gy(45)). It appears that at the lower heart doses observed using modern
radiotherapy techniques, SPECT cardiac imaging studies cannot identify a relationship
between dose and defects until 3-6 years following treatment (100). This delay impedes
our ability to understand the progression of the disease in humans and also requires
lengthy studies to assess the benefits of newer treatment strategies and/or techniques.
Currently, SPECT cardiac imaging for the detection of perfusion defects is either
assessed qualitatively and/or semi-quantitatively. The use of tracer kinetic modelling and
dynamic SPECT imaging is currently an active area of research and can potentially allow
for earlier assessment of radiation-induced perfusion defects(101). Although positron
emission tomography is not as widely available as SPECT, the implementation of
absolute cardiac perfusion quantification is well-established.

1.6.3.2

Cardiac PET imaging

To the best of our knowledge, PET has not been previously used to assess perfusion
changes following cardiac irradiation. The use of PET has advantages over SPECT due to
its ability to provide the quantification of myocardial perfusion in absolute units of
ml/min/g. Perfusion quantification requires quick and accurate measures of the radiotracer concentration within the myocardium. The temporal resolution of PET is typically
higher in comparison to conventional SPECT systems due to better count sensitivity.
Additionally, the temporal resolution in conventional SPECT systems are limited by the
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need to rotate the detectors around the patient. However, newer state of the art SPECT
systems can have temporal resolution of ~ 10s , which is similar to PET(102). In terms of
accuracy in quantifying tracer concentration, SPECT is limited by the ability to correct
for photon attenuation and scatter. Although SPECT attenuation and scatter correction
techniques have been validated, they are not as well established as PET attenuation
correction methods. Furthermore, both imaging modalities are limited by their poor
spatial resolution. This limitation currently hinders the ability to detect non-transmural
cardiac injury.
Attenuation refers to the reduction in the intensity of the photons as they traverse the
body towards the PET or SPECT detectors. To correct for this loss in intensity, the
distance travelled by the photons and the probability of interaction across that same path,
commonly referred to as the linear attenuation coefficients are needed. This information
can be approximated using CT as the signal intensity in CT is known to be directly
proportional to the linear attenuation coefficient. Estimating the attenuation path length
travelled by the photons in PET is more straightforward than SPECT.
In SPECT, the nuclear decay of the radio-tracer will result in a single photon emission.
However, in PET, the nuclear decay results in the emission of a positron. Upon emission,
the positron will become annihilated following collision with an electron. The
annihilation of the electron and positron releases two mono-energetic photons travelling
in directly opposite directions. PET takes advantage of this process by monitoring the
presence of a pair of coincidental detector events. The line traced out between two PET
detectors sharing a coincidental event gives an approximation of the total distance
travelled by the photons. Since these coincident events do not occur in SPECT, the
distance travelled by the photons must be estimated through more complicated
approaches described elsewhere (103). Assuming these and other corrections can be
made such that the signal is a good approximation to the tracer concentration, tracer
kinetic modeling can be used to quantify absolute measures of myocardial perfusion.
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1.6.3.3

Tracer kinetic modelling for myocardial perfusion

Three main PET tracers have been utilized for myocardial perfusion quantification; 1)
15

O labelled water, 13N labelled ammonia, and 82Rubidium (104–106). Although multiple

tracer kinetic models exist for each of these perfusion tracers; our discussion will be
limited to the 1-compartment model for

13

N labeled ammonia since this model is used

specifically in Chapters 3 and 4 of this thesis(107).
Several key assumptions are needed to simplify the process of estimating perfusion. The
first and most important assumption is that the time-varying radio-tracer concentration
within the vessel (intravascular space) and outside the vessel (extravascular
compartment) can be measured accurately. Additionally, it is assumed that the contrast
agent is well-mixed within these compartments such that the concentration is uniform
throughout. Figure 1-6 shows a visual representation of the 1-compartment model used
for the estimation of

13

N-ammonia perfusion. The single compartment represents a

volume of myocardial tissue surrounding the capillaries.

Figure 1-6: Visual representation of the one-compartment model. K1 represents the
rate of tracer accumulation within the extravascular compartment, measured in
units of ml/min/g. The rate at which the tracer washes out of the compartment is
defined as K2, measured in units of min-1.
The rate of tracer accumulation within the extravascular compartment is defined as K1,
measured in units of ml/min/g. The rate at which the tracer washes out of the
compartment is defined as K2, measured in units of min-1. The rate of change of tracer
concentration within this compartment is described by the following differential equation:
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𝑑𝐶𝑡𝑖𝑠𝑠𝑢𝑒 (𝑡)
= 𝜌𝐾1 𝐶𝑏𝑙𝑜𝑜𝑑 (𝑡) − 𝐾2 𝐶𝑡𝑖𝑠𝑠𝑢𝑒 (𝑡)
𝑑𝑡

(1-1)

where Ctissue, Cblood, and ρ represent the radio-tracer concentration in the tissue
(extravascular compartment), concentration in the blood (intravascular space), and the
tissue density respectively. A worked solution to equation 1-1 is provided in Appendix B.
The quantities Ctissue and Cblood, are measured; the quantities K1 and K2 are fitted
parameters typically obtained from a least-squares regression algorithm. The quantities
Ctissue and Cblood are obtained from calculating the mean pixel intensities within regions of
interest in the myocardial tissue and left-ventricular cavity (see Figure 1-7). If the
percentage of tracer removed from the blood to the tissue is known, commonly referred
to as the extraction fraction; the perfusion can then be calculated from K1 using equation
2 as originally described by Renkin and Crone (108, 109):
𝐾1 = 𝐸 ∗ 𝐹

(1-2)

where, E and F represent the tracer extraction fraction and perfusion respectively.
Although PET and SPECT can target many specific patho-physiological processes,
myocardial SPECT perfusion has been the most interrogated sub-clinical end-point in
radiation induced cardiac toxicity studies. Other sub-clinical end-points have been
observed in mice following cardiac irradiation such as an increase in pro-inflammatory
cell signals(51, 52). Cardiac inflammation can be imaged using PET in humans and may
potentially be a novel sub-clinical marker of radiation-induced cardiac toxicity(110, 111).

1.6.3.4

Cardiac PET imaging of myocardial inflammation

The utility of cardiac PET for imaging the progression of myocardial inflammation
following cardiac irradiation is a major component of the third and fourth chapters of this
thesis. Here we provide a brief summary of this advanced imaging technique.
Cardiac inflammation can be imaged using a very common PET radio-tracer,
fluorodeoxyglucose (18F-FDG). 18F-FDG is a glucose analog that enters cells in
proportion to the rate of glucose metabolism and is trapped in proportion to the rate of
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glucose phosphoralation. Many different cells within the body, such as inflammatory
cells and cardiomyocytes regularly metabolize glucose. Since glucose uptake is present in
both inflammatory cells and cardiomyocytes, distinguishing these two tissues is not
possible with 18F-FDG unless glucose metabolism can be suppressed in one cell type and
not the other.

Figure 1-7: Dynamic

13N-ammonia

PET perfusion images that have been overlaid

on cardiac MRI for anatomical context. The standard uptake value (SUV) of

13N-

ammonia is quantified in regions of interest within the myocardial left ventricular
tissue and blood indicated by purple and yellow rings respectively. These regions of
interest act as measured surrogates for the radio-tracer concentration in the tissue
(extravascular compartment) and the concentration in the blood (intravascular
space) used in the 1-compartment kinetic model.
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Unlike inflammatory cells, normal cardiomyocytes favour fatty acid metabolism. Taking
advantage of the heart’s preferred utilization of free fatty acids allows us to suppress
normal

18

F-FDG uptake by cardiomyocytes. This is achieved through fasting (12-18

hours) followed by lipid administration (via fatty diet or lipid injection) prior to PET
imaging (110, 112). Prolonged fasting is used to lower blood insulin and blood glucose
levels, causing the heart to switch to fatty acid metabolism. The administration of lipids
prior to PET imaging is to provide the “starved” heart with sufficient metabolites to
further minimize the heart’s need for glucose and consequently minimizing the uptake of
18

F-FDG. Under these conditions, observed 18F-FDG uptake in the region of the heart is

thought to be related to the metabolism of inflammatory cells and not the
cardiomyocytes. Figure 1-8 shows an

18

F-FDG cardiac PET image of the same subject

with and without myocardial glucose suppression. Adequate glucose suppression is not
always achieved. The results from previous randomized trial indicated that under an
optimized protocol suppression can be expected in ~88% of healthy human patients(113).
This approach has been previously used to assess cardiac inflammation associated with
non-radiation induced cardiomyopathies such as post myocardial infarction (111) and
cardiac sarcoidosis (110).

18

F-FDG PET has been previously used as a non-invasive

means to study RIHD after stereotactic lung (114) and esophageal (115, 116)
radiotherapy. However, to the best of our knowledge cardiac PET inflammation imaging
has not been previously utilized to assess the progression of inflammation related to
radiation-induced cardiac toxicity using doses relevant to the breast cancer population.

1.6.4

Magnetic resonance imaging (MRI)

The technological advancements in the last 10-15 years have placed MRI at the forefront
of cardiac imaging. Cardiac MRI has a myriad of capabilities such as imaging of
myocardial edema, coronary stenosis, myocardial perfusion, fibrosis, and valvular
disease. During a single examination, MRI can provide a comprehensive cardiac work-up
without delivering ionizing radiation to patients, making it an excellent candidate for
longitudinal follow-up studies.
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Figure 1-8: Transverse and sagittal image slices of the 18F-FDG standard uptake
value (SUV) with (upper panels) and without (lower panels) the cardiac glucose
suppression protocol.
MRI is used to produce images that highlight differences in the 1 or more intrinsic
magnetic properties of different tissues within the body. In general, an image is produced
after a sample is magnetized within a large uniform magnetic field. Once magnetization
is complete, tissue types with differing magnetic properties cannot be distinguished from
each other until after the next step, commonly referred to as excitation. The excitation
step typically consists of interrogating the sample with a short radio-frequency pulse that
temporarily “knocks” all the tissue types away from the original magnetized state. After
the excitation is complete, the different tissue types return back to the original
magnetized state. However, the rate of this return will vary for different tissue types with
different magnetic properties. This return to the original magnetized state is commonly
referred to as relaxation. Different tissue types tend to have different relaxation rates.
This is the key physical distinction between tissues that allows MRI images to possess
excellent soft-tissue contrast. The final step is a carefully timed read-out of signal that is
produced during relaxation. Timing of the read-out is crucial since it is used to maximize
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the contrast between the different tissue types prior to complete relaxation. This process
of magnetization, excitation, relaxation, and read-out can be repeated until the desired
image quality is achieved. Brown et al provide a more comprehensive discussion of
MRI(117).
To the best of our knowledge, only a single full length article has been published where
cardiac MRI is used for the study of radiation induced cardiac toxicity in the left-sided
breast cancer population(118). Heggemann, et al performed cardiac MRIs of 49 left-sided
breast cancer patients at baseline, 6 months, 12 months, and 24 months following
adjuvant treatment. Temporary decreases in the contractile function of the heart that
resolved 24 months post radiation were observed. No evidence of fibrosis was presented;
fibrosis was assessed qualitatively through late gadolinium MRI contrast enhancement.
As stated by the authors, a major limitation of their study is low patient accrual due to the
extended duration of each imaging session. Numerous functional parameters can be
imaged with MRI and the lack of knowledge with regards to radiation-induced cardiac
disease makes it difficult to tailor a protocol to detect radiation induced cardiac toxicity.
Controlled large animal studies using clinically approved MRI sequences may be
beneficial towards the future implementation of MRI imaging protocols with an aim to
monitor the progression of radiation induced cardiac toxicity in humans.
For clarity, the information provided in this section is not intended to motivate the use of
MRI in the current thesis. The capabilities of MRI for assessing cardiac function were not
utilized in this thesis; however, future work may include an investigation of cardiac MRI
on the same subjects to assess RIHD.

1.6.5

Hybrid imaging techniques

Each of the imaging modalities discussed above have their inherent strengths and
limitations. Often times the strengths of one imaging method tends to be a weakness of
the other and vice versa. This leads to an inevitable compromise when choosing which
imaging modality is optimal. This problem has motivated the development of many
hybrid imaging systems in which two modalities are combined into a single system(119).
Arguably the most successful “marriage” between two imaging modalities was the
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combination nuclear emission tomography (SPECT or PET) with computed tomography
(CT). The successful combination of SPECT with CT and PET with CT has led to a
single imaging system with the ability to provide functional information such as
perfusion and cellular proliferation overlaid on anatomical cross-sections for context.
Additionally, attenuation correction obtained from the CT has significantly improved
image quality of SPECT and PET. Today virtually all commercially manufactured PET
systems come with a CT. Due to the success of these systems the commercial
development of rival PET-MRI and SPECT-MRI hybrid systems has emerged. Unlike
CT which is predominately used for anatomical imaging, MRI is capable of both
functional and anatomical imaging.
The complementary strengths of PET and MRI are shown in Figure 1-9. In the context of
this thesis, PET-MRI represents an attractive approach to understanding and monitoring
the progression of radiation-induced cardiac toxicity. As previously mentioned,
preclinical studies in mice have shown evidence of inflammation, changes in myocardial
perfusion, and transient increases in cellular proliferation(52). In humans, typically one
and at most two of the above functional parameters can be assessed in a single session
using PET-CT or SPECT-CT. Unlike PET-CT and SPECT-CT, PET-MRI acquires
images in true simultaneous fashion; therefore it has the potential to acquire more
functional information regarding the heart in a shorter imaging session. Most of the
hardware compatibility issues between the PET and MRI appear to have been sorted
out(120). However, the biggest limitation of PET-MRI is with regards to attenuation
correction for the PET images. Unlike CT, the MRI signal is not related to the linear
attenuation coefficients of matter. For example, although bone and lung are quite
different in terms of their ability to attenuate photons, they’re highly indistinguishable in
the majority of MRI pulse sequences. Due to the importance of this problem, MRI
attenuation correction has become a highly active area of research(121–123).
A commonly used approach for attenuation correction in MRI is to segment anatomical
areas corresponding to lung, fat, and tissue using a specialized MRI pulse sequence (124).
This is followed by a substitution of the original pixel intensities with discrete attenuation
coefficient values that are typically observed in lung, fat, and tissue. Validation against
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PET-CT attenuation correction for cardiac PET-MRI imaging is supported in the
literature(121). Although we are optimistic and excited with regards to this novel imaging
platform, a significant amount of research is needed to understand the ultimate role of
PET-MRI in cardio-oncology.

Figure 1-9: Radar diagrams of the relative strengths and weaknesses of MRI, PET,
and hybrid PET-MRI. This figure is adapted with permission from Shah NJ, et al.
J. Magn. Reson. 2013;229:101–115.
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1.7 Gaps in knowledge, challenges, questions, and
hypotheses
Cardiac side effects in left-sided breast cancer patients after post-operative radiotherapy
has become one of the most debated issues in radiation oncology (20, 125, 126). This is
because the number of patients at risk is large and many are young. The increased rate of
a major coronary event in breast patients is high, 1.32 relative risk of a major coronary
event in comparison to age-matched controls (17). The relative risks are even greater in
cohorts with pre-existing risk factors such as smoking (1.87) and diabetes (3.23) (17).
Fortunately, approaches such as active breathing control, can reduce the mean dose to the
heart during treatment. However, the benefits of these approaches and the means in
which they are assessed have been recently put into question(43, 126). The widespread
clinical adoption of active breathing control and other similar techniques aimed at
reducing mean heart doses during radiotherapy are directly impacted by the following
problems/challenges.
1. Guidelines for radiotherapy planning left-sided breast cancer are needed to
minimize the risk of radiation-induced cardiac toxicity. Currently, such a
guideline does not exist since the true relationship between cardiac dose and
cardiac toxicity remains uncertain. The risk of a major coronary event is often
cited to increase by 7.4% per Gy to the heart (17). However, due to inherent
difficulties in estimating the dose to the heart, the uncertainty in this value is
likely even higher than what is reported (95 % confidence interval, 2.9% to
14.5%). Thus, further work is needed to provide more accurate assessment of
dose to the heart and sub-structures such as the coronary arteries.
2. Since cardiac toxicity following breast radiotherapy is a latent side-effect of
treatment (~10-15 years post treatment), recently proposed strategies to mitigate
this effect cannot be assessed in a timely manner with current approaches.
The following questions have been formulated with the aim of helping to guide decisions
with regards to radiotherapy planning and delivery that can minimize radiation-induced
cardiac toxicity:
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1. Does respiratory motion impact left-side breast cancer radiotherapy planning in
terms of the accuracy of estimating doses to the heart, left-ventricle, and LAD?
2. Can the effects of heart, left ventricular, and LAD irradiation on myocardial
perfusion and inflammation be visualized using PET at radiation dose levels
comparable to modern left-sided breast radiotherapy?
3. Can the effects of cardiac irradiation be visualized using PET at earlier time
points in comparison to other previously used imaging modalities?
4. Is there a spatial relationship between the magnitude of dose and regional changes
in cardiac inflammation?
5. Is there a spatial relationship between the magnitude of dose and regional changes
in cardiac perfusion?
6. Are specific regions within the heart such as the arteries more sensitive to
radiation effects than others?
The answers to the above questions will be instrumental in the design of future clinical
studies looking to properly assess strategies for mitigating radiation induced cardiac
toxicity following radiotherapy. Lastly, we present two hypotheses: 1) regarding radiation
treatment planning of left-sided breast cancer and 2) regarding the assessment cardiac
responses to radiation treatment:
A significant variation in dose across heart structures is attributable to respiratoryinduced motion during left-breast cancer radiotherapy.
A reduction in left ventricular perfusion and an enhancement in inflammation is related
to local radiation dose levels within the heart.

1.8 Thesis outline
1.8.1

Radiation dose uncertainty associated with motion of the
heart, left ventricle, and left anterior descending artery during
left-sided breast radiotherapy (Chapter 2)

The second chapter of this thesis is adapted from an original research article,
“Assessment of Intrafraction Breathing Motion on Left Anterior Descending Artery Dose
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During Left-Sided Breast Radiation Therapy” published in the International Journal of
Radiation Oncology*Biology*Physics 2016 (in press; published online: February 12,
2016) by El-Sherif O, Yu E, Xhaferllari I, Gaede S.
In this chapter doses to heart, left ventricle, and LAD were calculated for 30 left-sided
breast cancer patients receiving radiation therapy. Radiation dose was calculated using
the clinical standard free breathing CT scans that do not account for respiratory motion
and was compared to calculations where respiratory motion was accounted for. The
impact of respiratory motion on heart dose was assessed through 4D-CT imaging and 4D
dose accumulation. The findings show that the clinical standard is appropriate for
measuring doses to the heart and left ventricle; however, a clinically significant
discrepancy exists for the LAD. Preclinical studies have suggested that the dose to the
artery may be of equal or greater concern than the dose to the heart. Thus, the results
from this study will aid future studies that aim to correlate artery dose to radiationinduced cardiac toxicity. Additionally, to the best of our knowledge this is the largest leftsided breast cancer patient study assessing dose to the heart, left ventricle, and LAD that
uses both modern day radiotherapy techniques and accounts for respiratory motion.
Results from this study are used in Chapters 3 and Chapter 4 to aid in the design of a
canine model of cardiac exposures from left-sided breast radiotherapy.

1.8.2

Early 18F-FDG and 13N-ammonia cardiac PET imaging in a
canine model following cardiac exposures associated with
breast cancer radiotherapy (Chapter 3)

The third chapter of this thesis is adapted from another original research article, “18FFDG and

13

N-ammonia Cardiac PET Imaging in a canine model of cardiac exposures

associated with breast cancer radiotherapy”, by El-Sherif O, Xhaferllari I, Sykes J, Butler
J, DeKemp R, Renaud J, Battista J, Wisenberg G, Prato F.S., Gaede S. The article has
been accepted pending revisions from Radiotherapy & Oncology.
In this chapter a canine model of cardiac exposures associated with left-sided breast
cancer radiotherapy is presented. The hearts of five canines were imaged using 18F-FDG
(inflammation tracer) and

13

N-ammonia (perfusion tracer) cardiac PET at baseline, 1
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week, and 4 weeks following cardiac irradiation. The delivered dose to the heart, left
ventricle, and LAD was designed to match the expected biological equivalent dose from a
multi-fractionated left sided breast cancer population (data obtained from Chapter 1). The
distribution of the dose was intentionally focused on the LAD and anterior apical portion
of the left ventricle. This resulted in a dose-gradient within the heart. Although this
specific dose gradient is not typically observed in patients, it allowed us to assess the
relationship between spatial dose deposition and cardiac injury. The results from this
study showed that cardiac PET can identify statistically significant increases in the uptake
of 18F-FDG and 13N-ammonia, as early as 1 week following cardiac irradiation. A spatial
relationship between dose and tracer uptake was not observed; rather the response to
radiation was global, affecting regions with higher dose in comparison to regions
irradiated at a substantially lower dose similarly.
These novel findings suggest that an increase in myocardial perfusion (beginning ~1
week post irradiation) occurs and is associated with a global inflammatory response
(increased FDG uptake). Further work is needed to establish a more concrete connection
between these early changes observed using cardiac PET with long-term cardiac toxicity.

1.8.3

The utility of 18F-FDG and 13N-ammonia PET for monitoring
the progression of cardiac inflammation and perfusion
following focused cardiac irradiation in canines (Chapter 4)

The fourth chapter of this thesis is a longitudinal follow-up of the same five subjects from
chapter 3. The aim of this study is to identify whether the changes observed in
myocardial perfusion and inflammation observed in chapter 3 are acute responses to
radiation or persistent. Here, the hearts of five canines were imaged using
(inflammation tracer) and

13

18F-FDG

N-ammonia (perfusion tracer) cardiac PET at 3 months, 6

months, and 12 months following cardiac irradiation.
The results of this study show that

18F-FDG

and

13

N-ammonia PET can be used for the

longitudinal assessment of myocardial perfusion and inflammation in association with
cardiac external beam irradiation. In response to cardiac irradiation, progressive increases
in FDG uptake, a non-invasive means of assessing inflammation were observed and
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supported by preliminary ex-vivo histology. A transient increase in myocardial perfusion
that returned to baseline levels (in 3 subjects) and below baseline levels (in 2 subjects)
was also observed. A global response to radiation was observed affecting regions with
high dose and low doses similarly;

further validation of this finding through more

complete histology is needed. These results provide support for the future use of 18F-FDG
and

13

N-ammonia PET imaging for the longitudinal assessment of previously proposed

treatment options aimed at reducing radiation induced cardiac toxicity in humans.
This study is expected to be submitted for publication in Radiotherapy & Oncology
pending a more comprehensive histological analysis of the ex-vivo cardiac samples. The
histology is currently underway.

1.8.4

Conclusions and Future Work (Chapter 5)

Here, the key findings from the previous chapters are summarized and potential future
related studies are proposed and motivated.
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Chapter 2

2

Radiation dose uncertainty associated with motion of
the heart, left ventricle, and left anterior descending
artery during left-sided breast radiation therapy

Postoperative radiotherapy (RT) is the standard of care for breast cancer patients.
Technological advances in medical imaging and RT have led to significant improvement
in the survival rate of these patients (127). However, a portion of breast cancer survivors
are now exhibiting the latent effects of normal tissue irradiation, namely, radiationinduced ischemic heart disease (RIHD)(125). Due to proximity, left-sided breast cancer
(BREL) patients’ hearts are partially irradiated during RT, placing them at a greater risk
of RIHD(17, 32, 128).
Tangential intensity modulated radiation therapy (IMRT)(129–131) delivered under freebreathing is widely used for cardiac dose-sparing(132, 133).Recently, motionmanagement techniques such as, active breathing control (ABC), deep inspiration breathhold (DIBH), and inspiratory-gating (IG) have been proposed as options for reducing
incidental cardiac irradiation(134). Although numerous studies have shown that these
motion-management techniques can significantly reduce the dose to the heart, the clinical
benefits are still unknown. In a randomized trial, Zellars et al showed that the use of ABC
was not significantly associated with the prevention of cardiac perfusion deficits (43).
Preclinical studies suggest that the radio-sensitivity of the heart is heterogeneous and that
direct radiation exposure to specific regions within the heart, specifically, the major
coronary arteries are correlated with the acceleration of the atherosclerotic process(33,
48, 49). In light of these preclinical findings, the typically reported dose estimates for just
the heart volume alone may not be sufficient for assessing the efficacy of cardiac dose
sparing techniques. Doses to the heart may need to be supplemented with dose estimates
for the coronary arteries as well. Unfortunately, due to the impact of respiratory motion,
estimating the dose to the coronaries is difficult. Additionally, the standard of care for
left-sided breast RT uses a standard fast helical CT (FH-CT) for treatment planning that
does not account for internal organ motion during treatment simulation.
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To address this concern, the dosimetric impact of patient breathing on heart dose has
been previously quantified through the use of 4D-CT (83, 84, 87, 88). However, these
studies have not investigated the dosimetric impact on the cardiac sub-structures such as
the left ventricle (LV) and the left anterior descending artery (LAD). To better understand
the limitations of using standard FH-CT for left breast RT planning we have compared
DVH metrics for the heart, LV, and LAD regions obtained from the FH-CT to a 4D dose
accumulation.
The purpose of this study is to use 4D-CT imaging to predict the level of uncertainty in
cardiac dose estimates of the heart and its sub-structures that arises due to breathing
motion during RT. Additionally, the impact of potential errors associated with dose
deformation on the 4D dose accumulation within the heart, LV, and LAD is examined.

2.1 Methods and Material
2.1.1

Imaging

Institutional review-board approval was obtained to retrospectively analyse the planning
CT data of 30 consecutive patients whom have previously undergone RT for left-sided
breast cancer. The study design is outlined in Figure 2-1. As standard of care within our
institution, all BREL patients receive both a standard fast-helical CT (FH-CT) and a 4DCT for RT planning. The FH-CT and 4D-CT were acquired using a 16-slice Philips
Brilliance large bore CT scanner (Philip Medical Systems, Milpitas, CA). The Varian
RPM system (Varian Medical Systems, Palo Alto, CA) was used to monitor the motion
of an external fiducial positioned on the patient during 4D-CT imaging. The fiducial
provides a surrogate for the internal organ motion during normal respiration and is used
to sort the 4D-CT data into 10 separate breathing phases.

2.1.2

Treatment planning

Treatment plans were created on the FH-CT using the Pinnacle3 treatment planning
system (Philips Radiation Oncology Systems, Fitchburg, WI). Dose calculations were
performed with the collapse cone convolution algorithm and tissue inhomogeniety
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correction implemented in Pinnacle3.A Summary of the patient treatment characteristics
for

this

study

can

be

found
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Appendix B: Worked general solution to equation 1-1

𝑑𝐶𝑡𝑖𝑠𝑠𝑢𝑒 (𝑡)
𝑑𝑡

1-1

= 𝜌𝐾1 𝐶𝑏𝑙𝑜𝑜𝑑 (𝑡) − 𝐾2 𝐶𝑡𝑖𝑠𝑠𝑢𝑒 (𝑡)

begin by taking the Laplace transform of both sides of equation 1-1
𝑑𝐶𝑡𝑖𝑠𝑠𝑢𝑒 (𝑡)

𝐿{

𝑑𝑡

} = 𝐿{𝜌𝐾1 𝐶𝑏𝑙𝑜𝑜𝑑 (𝑡) − 𝐾2 𝐶𝑡𝑖𝑠𝑠𝑢𝑒 (𝑡)}

in the Laplace domain we have the following equation
̅
̅
̅
(𝑡) − 𝐶𝑡𝑖𝑠𝑠𝑢𝑒 (0) = 𝜌𝐾1 𝐶𝑏𝑙𝑜𝑜𝑑
(𝑡) − 𝐾2 𝐶𝑡𝑖𝑠𝑠𝑢𝑒
𝑠𝐶𝑡𝑖𝑠𝑠𝑢𝑒
(𝑡)

A-1

̅
(𝑡) 𝑎𝑛𝑑 𝐶𝑡𝑖𝑠𝑠𝑢𝑒 (0) are the Laplace transform of 𝐶𝑡𝑖𝑠𝑠𝑢𝑒 and the initial
where 𝐶𝑡𝑖𝑠𝑠𝑢𝑒
condition in the time domain respectively. Since the initial condition is equal to zero we
̅
(𝑡)
can rearrange equation A-1 to solve for 𝐶𝑡𝑖𝑠𝑠𝑢𝑒
̅
(𝑡) =
𝐶𝑡𝑖𝑠𝑠𝑢𝑒

𝜌𝐾1 𝐶̅𝑏𝑙𝑜𝑜𝑑 (𝑡)
𝑠+ 𝑘2

̅
̅
(𝑡) = 𝜌𝐾1 𝐶𝑏𝑙𝑜𝑜𝑑
(𝑡)
𝐶𝑡𝑖𝑠𝑠𝑢𝑒

1
𝑠 + 𝑘2

The following equation is obtained by taking the inverse Laplace transform of both
sides. Also, recall that multiplication in the Laplace domain is convolution in the time
domain.

𝐿−1𝐶𝑡𝑖𝑠𝑠𝑢𝑒𝑡=𝐿−1𝜌𝐾1𝐶𝑏𝑙𝑜𝑜𝑑𝑡⊗𝐿−11𝑠+ 𝑘2
𝐶𝑡𝑖𝑠𝑠𝑢𝑒 (𝑡) = 𝜌𝐾1 𝐶𝑏𝑙𝑜𝑜𝑑 (𝑡) ⊗ 𝑒� − 𝐾2𝑡
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Appendix C
.

Figure 2-1: Outline of study design. Abbrev: LV=
left ventricle; LAD = left anterior descending artery.
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2.1.3

4D dose accumulation

When performing the 4D-dose accumulation, each phase of the 4D-CT was weighted
equally. Due to patient variability in breathing, time-weighted dose accumulations may
be necessary, specifically when the 4D-CT is reconstructed in amplitude mode (135).
However, when a 4D-CT is reconstructed in phase mode, the equally weighted approach
has some inherent probability-weighting (135). This can be observed by examining the
position of the heart in the 40 -70% phases. The 40-70% phases all tend to be close to the
end of exhalation from an amplitude perspective (see Figure 2-2). To obtain the
accumulated dose distribution, the FH-CT was registered to the 4D-CT then the finalized
FH-CT treatment fields and isocenter were transferred to each phase of the 4D-CT. An
automatic rigid registration was performed between the FH-CT and 4D-CT minimizing
the squared differences of the voxel intensities. The quality of the registration between
the FH-CT and 4D-CT phase were verified qualitatively by visually comparing the
alignment of the vertebral bodies. The dose was recalculated on each of the phases. The
DICOM RT dose files were then exported from Pinnacle to MIMVista (MIM Software
Inc., Cleveland, OH, version 6.4.3) to obtain the deformable dose accumulation. The
warped doses were accumulated to the 50% phase of the 4D-CT for all patients, the heart,
LV, and LAD contours on the 50% phase of the 4D-CT were the ones used in our
comparison with the FH-CT.

Figure 2-2: A) Respiratory trace of a representative patient. The 5 coloured boxes
outline the amplitude divisions of the RPM trace corresponding to the end of
exhalation (EOE), end of inhalation (EOI), preEOE, preEOI, and mid ventilation
(midVENT) respiratory amplitudes. (B) The corresponding RPM derived frequency
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distribution for each respiratory phase. (C) Amplitude of the craniocaudal centroid
position of the heart contour for each 4D-CT phase of a representative patient.

2.1.4

Contouring and dose warping accuracy

To improve the accuracy of our contours, we employed a previously validated cardiac
atlas(136). Contours were originally drawn on the FH-CT then propagated to all 10
phases of the 4D-CT through the deformation algorithm within MIMVista (137). Autopropagated contours were reviewed and edited for any delineation errors. Additionally, to
account for dose uncertainty to the LAD due to cardiac motion, all LAD contours were
created with a standard 5mm diameter (58).
The mean spatial error of the deformation algorithm has been previously estimated to be
1.5mm(137–139). The sensitivity of the DVH metrics due to the uncertainty in the dose
deformation is estimated through rigid translation of the contours in three directions. All
contours associated with the dose accumulation were shifted in the anterior-posterior and
lateral-medial directions by ±0.75mm, ±1.5mm, ±3.5mm, and ±7.0mm. These shift
values are in line with previously reported deformation errors associated with MIMVista
(137–139). It should be noted that the max reported error can be up to 20mm, however, a
conservative max of 7 mm is considered here with the following justification; Nie et al
showed that in the presence of added image noise,<4% of the total voxels can be
expected to have deformation errors >7 mm and the max reported error of 20mm are
present in less than 1% of the volume (140). Additionally, the 20 mm error may not be
relevant here considering this value exceeds the magnitude of total respiratory induced
heart motion. Due to the slice thickness being 3mm, superior-inferior translations of
±3.5mm and ±7.0mm were only performed. Variation in dose due to translation is
inevitable even without dose warping since many of these contours are in close proximity
to high spatial dose gradients. Thus the FH-CT contours were translated along the unwarped dose distribution for comparison. Dose variation is reported in all three directions
as the dose difference (mean ± standard error of mean) between the translated contours
and the original fixed contours. A paired samples t-test was used to compare means from
the shifted 4DCT contours on the warped dose distribution to the shifted FH-CT contours
on the un-warped dose.
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2.1.5

Statistics and data analysis

Student’s paired t-test (p values< 0.05 were considered statistically significant) and
Bland Altman plots were used to assess the level of agreement between FH-CT and 4D
dose accumulation(141). As suggested by Bland et al, the 95% confidence interval of the
difference in the measures is used to illustrate how far apart the dose estimates from 4D
dose accumulation and FH-CT are likely to be for most patients. Prior to checking for
statistical significance, Shapiro-Wilk tests were performed to verify the normality
assumption required by the t-test.

2.2 Results
2.2.1

Delineation errors associated with auto-propagation

All contours were manually contoured on the FH-CT with guidance from a validated
cardiac atlas(136). Auto-propagation of these contours from the FH-CT to the 4D-CT
required some minor manual editing for the LAD contour only, the heart and LV
contours did not have any obvious delineation errors. The auto-propagation produced the
following 2 errors with the LAD contour; 1) shrinking of the LAD contour and 2)
splitting of the LAD contour into 2 separate ROIs within the same slice. Shrinking of the
LAD contour is problematic due to the spatial uncertainty of the LAD caused by cardiac
motion (58). These errors were addressed as follows; the LAD contours were expanded to
ensure a standard 5mm margin. Split LAD contours were qualitatively judged based on
which of the two contours were closest to the expected anatomical position of the LAD.
The LAD typically originates from the left main artery and then runs down the
interventricular groove, between the left and right ventricles. The contour closest in
proximity to this definition is kept and the other is deleted.

2.2.2

Dosimetric comparisons

The irradiated volume of the heart and LV typically exhibited minimal differences when
comparing the FH-CT to each phase of the 4D-CT. However, larger differences in
irradiated volume were observed in the estimated dose to the LAD region. The LAD
region’s potential sensitivity to motion can be visualized in Figure 2-3. The LAD is
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typically situated in close proximity to the steep dose-gradients along the beam edges of
the tangential fields.

Figure 2-3: A comparison of the fast helical CT (FH-CT), end of exhalation, and end
of inspiration radiation dose distributions for a representative patient. The heart,
left ventricle (LV), and left anterior descending artery (LAD) are outlined in
magenta, yellow, and red respectively. Differences in the irradiated volume and
magnitude of the heart, LV, and LAD are outlined by the white arrows for
comparison.
Figure 2-4 shows differences between EOI, EOE, and the 4D accumulated DVHs of the
heart, LV, and LAD for a representative patient. The comparison of the mean dose
difference between FH-CT and 4D accumulated doses for all patients is shown in Figure
2-5. Overall the dose differences were generally minimal for the heart and LV. The
average ± 95% confidence interval of 4D accumulated dose and FH-CT differences in
mean dose estimates for the heart, LV, and LAD were 0.1 ± 0.5 Gy, 0.0 ± 1.0 Gy, and 0.5 ± 8.7 Gy respectively. The average ± 95% confidence interval of 4D accumulated
dose and FH-CT differences in V50% for the heart and LV were 0.8 ± 1 % and 1.0 ± 3%
respectively. The FH-CT appears to underestimate for the maximal dose to 0.2 cc of the
LAD in comparison to the 4D accumulated dose by 1.3Gy ± 4.4Gy (mean ± SD). The
uncertainty in the dose accumulation due to errors in deformation was assessed by
comparing dose estimates after a rigid translation of the contours in three directions.
Additionally, the spread of the warped dose can be interpreted as the uncertainty in the

48

mean heart, LV, and LAD dose metrics. The results of this analysis are presented in
Table 2-1. Shifting of the heart and LV contours in the medial-lateral and anteriorposterior directions on the warped 4D dose did not result in any statistically significant
differences in comparison to the same contour shifts on the un-warped FHCT dose.
Superior-inferior shifts of the heart contour resulted in a significant difference, however,
the magnitude of this difference is small (warped dose: 0.30Gy ± 0.03; un-warped dose:
0.33Gy ± 0.03 for a 7mm shift).Similarly, 7mm superior-inferior shifts of the LV had
statistically significant but likely clinically insignificant differences (warped dose:
0.45Gy ± 0.05; un-warped dose: 0.50Gy ± 0.06) since they are within the patient setup
uncertainty of the treatment. For the LAD, medial-lateral, anterior-posterior, and
superior-inferior shifts on the warped dose were statistically different from the shifts on
the un-warped dose. The largest difference was observed for the medial-lateral shifts of
7mm (warped dose: 4.36Gy ± 0.37; un-warped dose: 4.98Gy ± 0.40).

2.3 Discussion and conclusions
The results of our study show that the mean dose to the heart and LV exhibit small to
moderate variations across a typical BREL patient’s breathing cycle, typically less than ±
0.5 Gy for the mean heart dose and ± 1.0 Gy for the mean LV dose. However, no
significant bias was observed between the 4D-CT and FH-CT derived cardiac DVH
metrics. This finding is in agreement with several previous publications that also used
4D-CT for the assessment (83, 84, 87, 88). The variation in mean heart dose due to
intrafraction motion (movement during imaging/treatment) shown here is on the same
order of magnitude as previously reported errors expected due to potential organ
delineation inaccuracies, 0.14±0.14 Gy (136). Similar to the heart, the errors due to
intrafraction motion of the LV appear to be only slightly larger than inaccuracies due to
delineation, ±1.0 Gy vs ±0.3Gy for the LV (136).The heart and LV are relatively large
volumes and typically only a small proportion of these volumes are within the region of
the dose distribution where the dose-gradient is steep. Thus, movements of the heart and
LV in the medial-lateral or superior–inferior directions cause minor variations in the
overall mean dose estimates to these structures. However, the heart is an organ composed
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of many different tissues that are integral to maintaining functionality. To date, the
variation in radio-sensitivity of the various tissues within the heart is poorly understood.

.
Figure 2-4: Variation between the end of inspiration (EOI), end of exhalation
(EOE), and 4D dose accumulation (4D) dose volume histograms (DVH) of a
representative patient. Variation in dose to the heart, left ventricle (LV), and left
anterior descending artery (LAD). (B) is an inset of (A).
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Figure 2-5: Bland Altman plots showing the level of agreement between the 4D dose
accumulation 4D-dose and the fast helical CT (FH-CT) mean dose estimates for the
heart (A), left ventricle (B), and LAD (C). The blue and red lines indicate the mean
difference and 95% confidence interval respectively for all 30 patients.
Table 2-1: differences in mean dose between shifted and un-shifted contours on
warped and unwarped dose distributions
Planned
Dose

Medial-Lateral Shift

Anterior –Posterior Shift

warped

unwarped

P

warped

warped

unwarped

p

±0.75 mm

0.11±0.01

0.11±0.01

0.80

0.15±0.01

0.15±0.01

±1.50 mm

0.20±0.02

0.20±0.02

0.97

0.26±0.03

0.26±0.02

0.81

--

--

--

0.46

--

--

±3.50mm

0.42±0.03

0.42±0.03

0.85

0.55±0.05

--

0.54±0.05

0.28

0.15±0.02

0.16±0.02

0.04

±7.00mm

0.82±0.06

0.82±0.06

0.96

1.07±0.10

1.05±0.10

0.16

0.30±0.03

0.33±0.03

<0.01

±0.75mm

0.16±0.02

0.16±0.02

±1.50mm

0.28±0.03

0.29±0.03

0.86

0.21±0.02

0.21±0.02

0.80

--

--

--

0.73

0.37±0.04

0.37±0.04

0.95

--

--

±3.50mm

0.60±0.06

--

0.60±0.06

0.56

0.78±0.09

0.79±0.09

0.89

0.23±0.03

0.25±0.03

0.16

±7.00mm

1.16±0.11

1.18±0.11

0.54

1.53±0.16

1.54±0.17

0.86

0.45±0.05

0.50±0.06

0.02

±0.75mm

0.61±0.05

0.70±0.05

0.02

0.85±0.07

0.91±0.07

0.19

--

--

--

±1.50mm

1.09±0.09

1.22±0.09

0.02

1.52±0.13

1.62±0.12

0.24

--

--

--

±3.5mm

2.29±0.19

2.60±0.20

0.01

3.17±0.27

3.42±0.27

0.13

0.80±0.08

1.99±0.09

<0.01

±7.00mm

4.36±0.37

4.98±0.40

<0.01

5.90±0.53

6.49±0.55

0.04

1.63±0.16

2.00±0.16

<0.01

Heart

LV

unwarped

Superior – Inferior Shift
p

2.34±0.06

3.19±0.19

LAD

11.93±0.63

Tabulated values represent the differences in mean dose between shifted and un-shifted contours (mean ± standard error of mean). Dose differences
are reported in absolute units of Gy. Boldfaced values indicate statistically significant differences between shifts on warped doses vs shifts on un-warped
doses (p<0.05)
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What is known is that the function of arteries and microvasculature within the heart can
be compromised through radiation exposure(33). Our use of 4D-CT and 4D-dose
accumulation have shown that incorporating the movement of the heart provides added
information with regards to the blurring of the dose during radiotherapy. Additionally, we
have shown that the area of the heart that may be of most concern, is the LAD, however,
further validation in clinical studies is still needed to better understand the relationship
between LAD irradiation and RIHD. The use of 4D-CT in potential future work in this
area is suggested to obtain more accurate dose estimates to the LAD.
The irradiated volume of the LAD was shown to have a much greater variation due to
respiratory induced motion than both the heart and LV; ± 8.7 Gy for the mean LAD dose.
To the best of our knowledge this is the first time the impact of intrafraction motion on
LAD dose has been reported. A previous study examined the displacement of the LAD
and showed the respiratory induced motion can lead to displacements as large as 9mm
towards the chest wall(84). These reported LAD displacements are consistent with what
was observed in this study. The visibility of the LAD on both FH-CT and 4D-CT is
difficult and the accuracy of the contour without the use of IV contrast is a limitation for
this study. However, this study shows that errors due to intrafraction motion of the LAD
appear to be larger for patients than the uncertainty that arises due to contouring
inaccuracies, ± 8.7 Gy vs 2.56Gy(136).
Another source of uncertainty comes from the dose deformation algorithm. However, the
95% confidence intervals for the errors associated with the intrafraction breathing motion
of the LAD appear to exceed the errors associated with dose deformation. Dose
deformation uncertainty was assessed here using rigid translations of the contours (Table
2-1).The small differences observed between the warped plan and the unwarped plans
suggest good agreement between the local dose gradient magnitudes. Shifting the LAD
contour by the mean expected error of the deformation algorithm (1.5mm)resulted in an
uncertainty in the LAD dose of ~1.5 Gy, less than the variation observed due to
intrafraction breathing motion (± 8.7 Gy). The 7mm shifts representing a “conservative
max” error of the deformation algorithm resulted in large variations in the estimated LAD
dose (5.9 Gy). Previous studies have reported <4% of the total voxels to have
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deformation errors of this magnitude(140).Thus, although the likelihood of a 7mm error
in deformation appears to be small, inaccuracies in the dose deformation of this
magnitude will have a significant impact on reported dose estimates to the LAD. A
limitation of this analysis is that the total uncertainty due to deformation is difficult to
quantify for small structures in close proximity to high dose gradients such as the LAD.
Further investigation of the uncertainty in the dose accumulation for this patient cohort is
still warranted.
The concern for dose deposition to the LAD for BREL patients is substantiated by the
proportion of these patients presenting with clinically significant coronary stenosis of the
LAD and myocardial perfusion defects that are isolated to myocardial segments known to
be supplied by the LAD (18, 59, 142, 143).
This study assumes that the respiratory trace of the external surrogate during 4D-CT
simulation is reproducible during RT. Although, patient breathing likely varies from day
to day, a previous study reported good day to day reproducibility of probability
distributions for lung tumour motion(144). We expect similar reproducibility considering
the respiratory induced motion of the heart is more subtle than that of a lung tumour.
Although the 4D-CT may provide added information with regards to the motion of the
internal anatomy, there is an added risk of radiation-induced malignancies due to the
increased dose from the 4D-CT. The effective dose from 4D-CT is approximately 8 times
the dose from a conventional FH-CT(145) (~6mSv vs ~48mSv).The lifetime attributable
risk (LAR) for fatal cancer induction was estimated in adults to be 33 cases per 100,000
standard chest CT examinations (~0.03%)(146). An approximated LAR from a 4D-CT
can be expected to yield 231 more cases per 100,000 (~0.2%). Studies have shown that a
reduction in heart dose by 1Gy correlates to a 7.4% decrease in the rate of a major
coronary event(17). The 0.2% increased LAR for the induction of a fatal cancer due to
the added exposure from 4D-CT can be potentially outweighed by just a small reduction
in the heart dose (~0.03Gy to avoid a coronary event or ~1.2 Gy to avoid death due to
heart disease). Thus, prior to the adoption of 4D-CT for left-sided breast treatment
planning, further work is needed to identify if the added information from the 4D-CT can
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be successfully used in the treatment planning process to reduce the dose to the heart,
LV, and/or LAD.
In conclusion, we found small variations in the dose to heart and LV due to intrafraction
respiratory motion during RT. However, the LAD showed substantial variation in dose
due to breathing. Although the respiratory induced variations in LAD dose may not have
an immediate clinical impact, we suggest that future clinical studies looking at the
relationship between RIHD and LAD dose to consider the use of 4D dose accumulation
rather than relying on the static treatment planning methods of the past.

54

Chapter 3

3

Early 18F-FDG and 13N-ammonia PET imaging in a
canine model following cardiac exposures associated
with breast cancer radiotherapy

Chapter 3 hypothesis: A reduction in left ventricular perfusion and an enhancement in
inflammation is related to local radiation dose levels within the heart.
Advances in imaging and radiotherapy have led to significant improvement in the
survival rate of breast cancer patients(127). However, several recent studies have shown
that a large proportion of breast cancer patients show evidence of late radiation induced
ischemic heart disease (RIHD)(16, 17, 147) following tangential external beam
radiotherapy. Due to the development of new techniques many patients are living longer.
Previously latent effects of radiation are now being seen. The relative risk of ischemic
heart disease is believed to be proportional to the volume of the heart that is irradiated
during therapy(17). To address this concern, some cancer clinics are now using
respiratory motion management techniques, such as deep inspiration breath-holding
(DIBH), to add greater spatial separation between the heart and the left-breast during
radiotherapy(148, 149). The use of DIBH has been shown to reduce the irradiated volume
of the heart. Unfortunately, due to the close proximity of the heart to the left breast, the
DIBH technique cannot completely eliminate the incidental cardiac irradiation associated
with radiotherapy. Reported average doses to the myocardium and the left anterior
descending artery (LAD) in patients treated with DIBH can be up to 2Gy and 8Gy,
respectively(148). Cancer centers using tangential fields that have not adopted the DIBH
technique can see average doses as high as 6 Gy and 32 Gy to the myocardium and LAD,
respectively. It is believed that the relative risk of a major coronary event increases by
7.4% per Gy without any evidence of a threshold dose below which there is no added
risk(17).The pathogenesis of RICD is not well understood and clinical symptoms do not
typically manifest until 10-15 years after radiotherapy. However, a recent study in mice
identified significant up-regulation of inflammatory markers expressed on the vascular
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endothelium in response to radiation(52), suggesting changes in the microvasculature
developing as early as 10 and up to 20 weeks post-irradiation.
18

F-FDG PET has been previously used as a non-invasive means to study RICD after

stereotactic lung(114) and esophageal(115, 116) radiotherapy. Mean doses to the heart
after lung and esophageal cancer are typically greater than 20 Gy, higher than what is
observed in breast cancer patients. As previously described in Chapter 1, the cardiac
injuries observed at high doses (i.e. pericarditis) are different from those observed at
lower doses (i.e. ischemia). Due to this difference in the expected radiation induced
injury to the heart, extrapolating the results from lung and esophageal studies to set
guidelines for left-sided breast cancer radiotherapy is uncertain. Additionally, the
majority of pre-clinical studies on this topic have used murine models; however,
significant differences have been identified in comparison to human physiology. Further,
large animal models have been suggested for easier translation of basic science findings
to clinical practice, as they offer a more representative scale model of cardiac human
physiology than murine models(150). Here we examine the utility of

18

F-FDG and

13

N-

ammonia cardiac PET for the assessment of radiation induced myocardial inflammation
and altered perfusion in a canine model.18F- FDG and

13

N-ammonia PET have been

previously validated as non-invasive means of quantifying cardiac inflammation(111)
and myocardial perfusion(151), respectively.18F- FDG and

13

N-ammonia PET can

potentially quantify regional heterogeneity in inflammation and perfusion concurrently
in association with the known patterns of regional dose deposition within the heart. In the
current study, changes in the uptake of 8F-FDG and

13

N-ammonia were quantified at

baseline, 1 week post, and 4 weeks post external beam cardiac irradiation. Irradiation was
designed to mimic the typical exposure observed during left-sided breast cancer
radiotherapy. This study aims to probe the spatial and quantitative relationship between
radiation dose-deposition and acute changes in perfusion and associated inflammatory
response.
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3.1 Materials and methods
3.1.1

Study design

Cardiac perfusion and inflammation imaging on five adult female, bred-for-research
hounds (21 -26 Kg) was performed on a hybrid PET/MRI system (Biograph mMR;
Siemens AG) at baseline, 1, and 4 weeks post cardiac irradiation (see Figure 3-1 for
details). Animals were anesthetized during imaging/irradiation using propofol (4-6
mg/kg) and maintained with 2% isoflurane. The study was approved by the Animal Care
Committee of the Western University (Protocol 2014-005, Appendix D). The choice for 5
subjects was supported by an a priori power analysis (G*power, Version 3.1.9.2). The
required number of samples was calculated such that the study would have a statistical
power ≥ 0.95, at a significance criterion (α-value) = 0.05. An estimated effect size was
derived from literature comparing perfusion estimates in normal volunteers to 5 groups of
patients with varying levels of myocardial ischemia(152).

Figure 3-1: An overview of the longitudinal study is shown in panel A. Timing of the
baseline, 1 week and 4 week follow-up PET/MRI imaging protocol is shown in panel
B. Abbrev. CT-SIM – computed tomography radiotherapy simulation scan; IV –
intravenous; MRAC – magnetic resonance attenuation correction.
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3.1.2

Radiation treatment planning & delivery

The radiation dose distribution was designed to resemble the typical cardiac exposure
delivered during left-sided breast cancer radiotherapy. Dose volume histogram (DVH)
metrics were obtained from 30 consecutive clinically treated left-sided breast cases at the
London Regional Cancer Program (London, ON Canada). The 95% confidence intervals
of the extracted DVH metrics were used as dose constraints for the heart and it’s
substructures in this study. A detailed summary of the included patient treatment
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characteristics

and

the

derived

dose

constraints

are

provided

in
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Appendix B: Worked general solution to equation 1-1

𝑑𝐶𝑡𝑖𝑠𝑠𝑢𝑒 (𝑡)
𝑑𝑡

1-1

= 𝜌𝐾1 𝐶𝑏𝑙𝑜𝑜𝑑 (𝑡) − 𝐾2 𝐶𝑡𝑖𝑠𝑠𝑢𝑒 (𝑡)

begin by taking the Laplace transform of both sides of equation 1-1
𝑑𝐶𝑡𝑖𝑠𝑠𝑢𝑒 (𝑡)

𝐿{

𝑑𝑡

} = 𝐿{𝜌𝐾1 𝐶𝑏𝑙𝑜𝑜𝑑 (𝑡) − 𝐾2 𝐶𝑡𝑖𝑠𝑠𝑢𝑒 (𝑡)}

in the Laplace domain we have the following equation
̅
̅
̅
(𝑡) − 𝐶𝑡𝑖𝑠𝑠𝑢𝑒 (0) = 𝜌𝐾1 𝐶𝑏𝑙𝑜𝑜𝑑
(𝑡) − 𝐾2 𝐶𝑡𝑖𝑠𝑠𝑢𝑒
𝑠𝐶𝑡𝑖𝑠𝑠𝑢𝑒
(𝑡)

A-1

̅
(𝑡) 𝑎𝑛𝑑 𝐶𝑡𝑖𝑠𝑠𝑢𝑒 (0) are the Laplace transform of 𝐶𝑡𝑖𝑠𝑠𝑢𝑒 and the initial
where 𝐶𝑡𝑖𝑠𝑠𝑢𝑒
condition in the time domain respectively. Since the initial condition is equal to zero we
̅
(𝑡)
can rearrange equation A-1 to solve for 𝐶𝑡𝑖𝑠𝑠𝑢𝑒
̅
(𝑡) =
𝐶𝑡𝑖𝑠𝑠𝑢𝑒

𝜌𝐾1 𝐶̅𝑏𝑙𝑜𝑜𝑑 (𝑡)
𝑠+ 𝑘2

̅
̅
(𝑡) = 𝜌𝐾1 𝐶𝑏𝑙𝑜𝑜𝑑
(𝑡)
𝐶𝑡𝑖𝑠𝑠𝑢𝑒

1
𝑠 + 𝑘2

The following equation is obtained by taking the inverse Laplace transform of both
sides. Also, recall that multiplication in the Laplace domain is convolution in the time
domain.

𝐿−1𝐶𝑡𝑖𝑠𝑠𝑢𝑒𝑡=𝐿−1𝜌𝐾1𝐶𝑏𝑙𝑜𝑜𝑑𝑡⊗𝐿−11𝑠+ 𝑘2
𝐶𝑡𝑖𝑠𝑠𝑢𝑒 (𝑡) = 𝜌𝐾1 𝐶𝑏𝑙𝑜𝑜𝑑 (𝑡) ⊗ 𝑒� − 𝐾2𝑡
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Appendix C and Appendix E respectively. All animals received a standard fast helical CT
and a contrast enhanced CT (Discovery VCT; GE Healthcare) for radiation treatment
planning. All subjects were ventilated using shallow breaths in order to minimize the
need to correct for intrafraction respiratory motion. Contours of the heart, left ventricle
(LV), left circumflex(LCX), and LAD were manually delineated on the contrast
enhanced CT for improved visualization. Myocardial regions of the left ventricle were
further segmented in accordance with the 17 segment model as described by the
American Heart Association( AHA)(153). Complete contours were overlaid onto the
non-contrast enhanced CT images for radiation treatment planning. Volumetric
modulated arc therapy(154) (VMAT) radiation treatment plans were created using the
Pinnacle3 treatment planning system (Phillips Radiation Oncology Systems). The
treatment plans consisted of two, 180o, 6 MV photon arcs and deliberately focused on to
the myocardial regions supplied by the LAD while intentionally avoiding the basal
anterolateral portion of the LV and the LCX in order to compare cardiac function in
irradiated vs minimally-irradiated segments. Dose was calculated using the adaptive
convolve dose algorithm(155–157) implemented in Pinnacle3.
During baseline imaging, tattoos, radio-opaque markers, and wall-mounted lasers were
used to aid with re-positioning of the animals on the day of irradiation. Prior to treatment,
cone-beam CT and intra-treatment fluoroscopic imaging were used to verify the position
of the animal’s hearts during irradiation.
The biological equivalent dose(158) of the multi-fractionated radiation prescriptions was
delivered in a single fraction. An α/β ratio of 2.5 Gy (159) was used to convert the multifractionated scheme (~30 Gy in 25 fractions prescribed to a point within the LAD) to a
single fraction delivery (~9 Gy in 1 fraction) (159). All animals were irradiated with a
TrueBeam linear accelerator (Varian Medical Systems).

3.1.3

Imaging

Cardiac perfusion and inflammation was assessed using 13N-ammonia and 18F-FDG PET
imaging, respectively (details outlined in Figure 3-1).
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Cardiac perfusion was imaged both under pharmacological stress and at rest.
Pharmacological stress perfusion was induced in all animals using 3 mg/min intravenous
injection of adenosine over 10 minutes. Adenosine was injected prior to the manual bolus
injection of

13

N-ammonia (~5 MBq/Kg) followed by a saline flush. Rest perfusion was

assessed with a second injection of 13N-ammonia. The data was acquired in list-mode and
retrospectively binned into time periods using the bellows respiratory trigger. The list
mode data was grouped into 16 frames: 12x10s, 2x30s, 1x60s, 1x360s. All PET data was
reconstructed using an iterative 3D ordered subset expectation maximization
algorithm(OSEM)(160) with 3 iterations, 21 subsets,172x172x127 matrix size, and a 4mm Gaussian smoothing filter, yielding a voxel size of 2.08x 2.08 x 2.03 mm. The hybrid
PET/MRI system corrects for random coincident events using the standard delayed
window correction method. For scatter correction, a single scatter iterative algorithm is
used. The scatter correction technique was originally described by Watson et al(161). The
dead time is measured empirically and applied as a correction to the PET signal after
normalization.
Prato et al, (111) previously described and validated an

18

F-FDG PET imaging protocol

capable of identifying abnormal accumulation of inflammatory cells within the heart
following coronary occlusion. The same imaging protocol is adopted here to study RICD.
In order to image cardiac inflammation, the normal myocardial uptake of glucose was
suppressed prior to the injection of 18F-FDG. The suppression of glycolysis was achieved
through fasting and an intravenous injection of heparin (2000 IU) immediately followed
by a 20% lipid (Intralipid; Baxter Health-care Corp.) infusion (0.25 ml/min/kg; 50 min
duration) 20 min prior to the injection of 18F-FDG. This myocardial suppression protocol
was validated before the current study in 3 healthy subjects. The data was acquired in listmode 60 mins after the injection of

18

F-FDG. A single static frame (20min duration;

respiratory triggered) was reconstructed using OSEM. Attenuation was corrected for all
PET scans using a 2-point Dixon MR imaging pulse sequence(124, 162), which
automatically segments and substitutes discrete attenuation coefficients of lung, adipose
tissue, and soft tissue. MR-based attenuation correction for cardiac PET has been
previously validated and shown to be strongly correlated with standard CT-based

63

attenuation correction with narrow Bland-Altman limits of agreement (-8.5% to
+12.6%)(23).

3.1.4

Data Analysis

Perfusion and inflammation results were grouped according to the typical canine
coronary artery distribution(163). Each of the 17 myocardial regions was classified as
being predominately supplied by the LAD, LCX, or both arteries.
Cardiac perfusion was quantified using a one-compartment tracer kinetic model(151)
implemented using the semi-automated analysis program, FlowQuant© (University of
Ottawa Heart Institute)(164). A unidirectional uptake rate constant, K1, from the arterial
blood to the tissue compartment provides a direct estimate of myocardial perfusion
(ml/min/g). This assumption has been previously shown to be valid since the tracer
extraction for

13

N-ammonnia is >92%(151, 165) for flows up to 6 ml/min/g. In general,

K1 is obtained from the deconvolution of the imaged-derived tissue tracer concentration
curve (obtained from each of the 17 myocardial segments) and the arterial input function
(obtained from a region interest within the left ventricular blood pool). The 1compartment model derivation of the relationship between the measured tracer
concentration in the blood, tissue, and the estimated K1 and K2 values is provided in
Appendix B. The K1 and K2 value is estimated through an iterative approach minimizing
the cost function defined in equation 3-1.
𝐶𝑡𝑖𝑠𝑠𝑢𝑒 (𝑡) − 𝜌𝐾1 𝐶𝑏𝑙𝑜𝑜𝑑 (𝑡) ⊗ 𝑒 −𝐾2 𝑡

3-1

Changes in cardiac inflammation were analyzed as changes in the mean standard uptake
value (SUVmean) and standard uptake ratio (SUR). The definition of the SUV is provided
in equation 3-2.
𝑆𝑈𝑉 =

Activity in myocardial region (MBq)/regional volume (ml)
Injected activity (Mbq)/ subject weight (g)

3-2

The SUR has been previously reported as a means of reducing inter-study variation. The
SUR value is obtained by normalizing the SUVmean by the SUV within the aorta(166).
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SUVmean and SUR were computed for all 17 myocardial regions defined by the AHA. For
statistical comparison, the 17 myocardial regions were aggregated and grouped based on
coronary regions (LAD vs LCX vs Both), axial regions ( basal vs mid-ventricle vs apex),
and radial regions ( lateral wall vs inferior wall vs anterior wall vs septal wall). Table 3-1
proves further details regarding this regional grouping.
Table 3-1: Grouping of American Heart Association 17 segment model for statistical
comparisons
Comparison Group 1

Comparison Group 2

Comparison Group 3

coronary regions

AHA segment

Axial Regions

AHA segment

Radial Regions

AHA segment

LAD

1, 2, 7, 8, 13

Basal

1-6

Anterior wall

1, 7, 13

LCX

4, 5, 10, 11, 15

Mid-ventricular

7-12

Septal wall

2, 3, 8, 9, 14

Both

3, 6, 9, 12, 14,

Apex

13-17

Lateral wall

5, 6, 11, 12, 16

Inferior wall

4, 10, 15

16, 17

All statistical analyses were performed using SPSS 23 (IBM Corp.). Differences in
cardiac perfusion and inflammation before and after irradiation and regional differences
between myocardial regions supplied by the LAD and LCX were tested using a
multivariate two-way repeated measures analysis of variance. Bonferroni post hoc
analysis was used to correct for multiple comparisons. Pearson’s product-moment
correlation coefficient was used to test the association between regional dose deposition
and changes in perfusion/inflammation. All data are reported as mean ± standard error of
the mean (SEM) unless otherwise indicated.

3.2 Results
The average regional dose, injected dose of all radiotracer, and plasma glucose levels
(PGL) prior to imaging are tabulated in
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Appendix F. No statistically significant differences were observed between scans for the
injected doses of

13

N-ammonia and

18

F-FDG. Although no statistically significant

differences were found between PGL, the baseline PGL and PGL at 4 weeks did
approach statistical significance (p =0.055). Mean doses delivered to the heart (1.7 Gy),
LV (2.7 Gy), LAD (5.5 Gy), and LCX (1.1 Gy) are typical of values observed in leftsided breast cancer radiotherapy patients. Figure 3-2 shows the computed radiation dose
distribution superimposed onto the contrast-enhanced CT image for a representative
subject. Figure 3-3 shows the DVH’s for the heart, LAD, and LV of a representative
subject in comparison with DVH’s of two patients analyzed in Chapter 2.

Figure 3-2: A coronal, contrast-enhanced CT slice (panel A) showing the heart, left
ventricle (LV), left anterior descending artery (LAD), and left circumflex artery
(LCX) contours on a representative subject (subject 3). The spatial distribution of
the radiation dose is shown in panel B. The basal anterolateral portion of the LV
and the LCX were intentionally avoided (see panel B) in order to compare cardiac
function in irradiated vs non-irradiated segments.
A statistically significant increase in the

18

irradiation. Increased cardiac uptake of

18

F-FDG SUVmean and SUR was observed post

F-FDG was found throughout the entire LV,

including targeted and un-targeted myocardial regions (see Figure 3-4). The change in
SUVmean and SUR aggregated from all 5 subjects is presented in Figure 3-5. A correlation
could not be established between regional dose and differences in uptake of
relative to baseline.

18

F-FDG
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A statistically significant increase in both rest and stress
post cardiac irradiation. Static

13

13

NH3 perfusion was observed

NH3 cardiac PET uptake images are shown for a

representative subject (subject 3) in Figure 3-6. Increased stress perfusion was found
throughout the entire LV, with no statistically significant difference between regions
regardless of regional dose magnitude (see Figure 5). Linear regression analysis between
dose and perfusion did not reveal any significant relationships between dose and
perfusion effects. The FDG uptake and resting state perfusion appear to progressively
increase within the first 4 weeks following cardiac irradiation.

3.3 Discussion
The risk of RICD after left-sided breast radiotherapy is substantiated by several
epidemiological studies; however, the early events and progression of the disease still
remain unclear. RICD is considered a significant health problem due to the large number
of women receiving radiotherapy for breast cancer(17, 32, 127) and surviving to an older
age where cardiac issues become evident. This study demonstrated that focal cardiac
irradiation to the LAD with heart doses comparable to that of standard breast irradiation
techniques results in an early increase in 18F-FDG uptake and myocardial perfusion. This
study also demonstrates that these changes can be detected as early as 1 week post
irradiation. It should be noted that collateral cardiac irradiation as a consequence of
breast radiotherapy is typically delivered with 30 dose fractions. However, this study was
performed using a single irradiation. In this study, the delivered single fraction dose was
set using a previously reported 𝝰/𝝱 ratio of 2.5 Gy(159). Evidence exists regarding the
validity of applying the linear quadratic model for single fraction deliveries(167),
although this matter is still debated (168, 169).
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Figure 3-3: Cumulative dose volume histogram comparison between human and
canine cohorts for the heart, LAD, and LV.
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Figure 3-4:

18F-FDG

SUV PET images of a representative subject (subject 3) at

baseline, 1 week and 4 weeks post cardiac irradiation.
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Figure 3-5: Changes in 18F-FDG mean standard uptake value (SUVmean) and
standard uptake ratios (SUR) obtained from regions of interest within the left
ventricle pre and post cardiac irradiation. Panels along the left and right column
represent changes in SUVmean and SUR respectively. Uptake in panels A and B are
grouped by myocardial regions supplied by the left anterior descending (LAD)
and/or the left circumflex artery (LCX). Uptake in panels C and D are grouped by
basal, middle (Mid) and apical (apex) myocardial regions. Uptake in panels E and F
are grouped by inferior, lateral, anterior, and septal myocardial regions. The mean
dose delivered is reported in the legend, error bars indicate the standard error of
the mean, and statistically significant differences are indicated by horizontal lines
spanning the comparison points as *p<0.05 and **p<0.01.
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Figure 3-6:

13NH

3

standard uptake value (SUV) PET images of a representative

subject (subject 3) at baseline, 1 week and 4 weeks post cardiac irradiation. Images
are reconstructed from list-mode data acquired 4 - 10 minutes post radiotracer
injection.
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Figure 3-7: Changes in 13N-ammonia myocardial perfusion obtained from regions of
interest within the left ventricle pre and post cardiac irradiation. Panels along the
left (i) and right (ii) columns represent perfusion changes observed at rest and
under pharmacological stress respectively. Panels A. i) and ii) are grouped by
myocardial regions supplied by the left anterior descending (LAD) and/or the left
circumflex (LCX). Panels B. i) and ii) are grouped by basal, middle (Mid) and apical
(apex) myocardial regions. Panels C. i) and ii) are grouped by inferior, lateral,
anterior, and septal myocardial regions. The estimated dose delivered is reported in
the legend, error bars indicate the standard error of the mean, and statistically
significant differences are indicated by horizontal lines spanning the comparison
points as *p<0.05 and **p<0.01.
It is believed that the earliest morphological changes to heart after irradiation are related
to the microvasculature. Pre-clinical evidence supports the hypothesis that an
inflammatory response following cardiac irradiation is a precursor and the mechanism for
the evolution of RICD(19). Here we have shown that during the suppression of
competing myocardial glucose uptake, a global increase in 18F-FDG uptake is triggered in
response to focused cardiac irradiation. We hypothesize that this increased uptake is
indicative of systemic inflammatory response to the radiation. The merits of this imaging
approach has been previously shown for assessing inflammation in cardiac
sarcoidosis(110) and after myocardial infarction(111). However, the ability to
successfully suppress the normal

18

F-FDG physiological uptake by myocardium is

difficult to verify and a potential limitation of this technique. Additionally, it has been
previously reported that anesthesia through the use of isoflurane may reduce the
suppressive effects of fasting and heparin on myocardial glucose utilization in mice(170).
Although we cannot be completely certain that full glucose suppression was achieved in
this study, we have shown depressed SUV values (Figure 3) at baseline and follow up in
comparison to previously reported SUV values without suppression(171). Furthermore,
although the imaging protocol was consistent throughout the study, we cannot completely
rule out potential for variability in the level of suppression between subjects and/or time
points and the spatial heterogeneity of suppression within subjects. Thus, additional tests
such as histopathology would be required to confirm the presence of inflammation.
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Unfortunately, histopathology confirmation could not be included since subjects were not
sacrificed at the conclusion of this acute study.
We observed similar heterogeneity in

18

F-FDG uptake throughout the different planes of

the LV compared to findings in previously reported literature(172, 173). Increased uptake
was observed in the mid and apical planes compared to the basal plane. No statistically
significant variation was found between inferior, lateral, anterior, and septal LV regions.
However, the trend in Figure 3-5, panel E is in agreement with the expected spatial
variation in uptake(174).

18

F-FDG uptake tends to be higher in the lateral and inferior

walls than the anterior wall and septum of normal myocardium. Three early explanations,
one technical and two physiological were previously provided for the observed
heterogeneity in normal myocardial FDG uptake, however they were refuted. In axial
PET images the septal/anterior LV walls appear thinner than the inferior/lateral walls.
Consequently, it was reasonably hypothesized that counts would be reduced in the
thinner portions of the LV. Additionally, potential variability in regional perfusion and
contractile work load of the LV has been previously provided as explanations for the
heterogeneous uptake. However, all three explanations were later refuted through the use
of

11

C-acetate (myocardial oxygen consumption tracer) and

15

O-water (perfusion tracer)

PET imaging(175). Groppler, et al, showed homogeneous myocardial perfusion and
clearance of

11

C-acetate from normal myocardium, suggesting that the previous

explanations for the heterogeneous uptake of FDG are unlikely. To the best of our
knowledge, no further explanations have been provided in the literature. All that we
know is that this heterogeneity is commonly observed(172, 174).
No correlation was found between the dose delivered to specific myocardial regions and
the change in uptake relative to baseline, i.e. the areas of higher radiation dose did not
appear to have greater increases in perfusion or FDG uptake with greater dose. To the
best of our knowledge, this dose-independent uniform global inflammatory response at 1
week post irradiation in the heart at dose levels comparable to what is observed in the
breast cancer population is a novel finding. The lack of correlation with dose magnitude
may be due to the small number of animals used in this study and also by the relatively
few myocardial regions with exposures below 1 Gy. Approximately 8% and 1% of the
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total number of contoured LV regions received doses less than 1 Gy and 0.5 Gy,
respectively. The clinical implication of this finding supports the recent interest in the use
of standard heart failure therapies such as ACE inhibitors as a potential strategy to reduce
the risk of RICD(176).
Clinical assessments

of myocardial perfusion post left-sided breast radiotherapy

consistently report reductions in myocardial perfusion at least 6 months after
radiotherapy (43, 45, 47, 59, 99, 177–180). However, results from this study show an
increase in myocardial perfusion 1 week after cardiac irradiation by approximately 20%
relative to baseline. This finding suggests that a transient increase in perfusion (~1 week
post irradiation) due to a global inflammatory response may precede reductions in
perfusion observed at 6 months. This may develop as a result of late fibrotic changes
within either myocardium or epicardial vessels leading to hemodynamically significant
stenoses. This increase in perfusion is in line with two pre-clinical studies in murine
models(181, 182). Lauk et al(181) and Seeman et al(182) observed increases in
endothelial cell proliferation (3 weeks post irradiation) and increases in microvascular
density 20 weeks following cardiac irradiation respectively. Additionally, an increase in
vascular permeability has been reported in mice, 4 weeks after partial cardiac
irradiation(80).
The uncertainty in the quantification of myocardial perfusion using

13

NH3 PET has been

previously reported as approximately 10%(104, 105). It is believed to be dominated by
variation in cardiac motion, signal noise, errors in compartmental modeling, partial
volume effects, spillover from the right ventricular blood pool/adjacent liver activity, and
potential errors in image registration between time points. However, the mean increases
in perfusion after cardiac irradiation relative to baseline shown here are greater than the
expected overall reported uncertainty in perfusion estimation.
It should be noted that the absolute measures of stress perfusion reported here appear to
be reduced in comparison to literature values with similar adenosine administration
protocols. This was a consistent finding in all animals and it is speculated that it may be
related to the dose of adenosine. This prompted an additional stress

13

NH3 PET scan in
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two animals with a double dose of adenosine; however, perfusion results at the double
dose still remained blunted. Previous studies have also reported difficulties with the use
of intravenous adenosine infusion in comparison to dipyridamole in the quantification of
myocardial blood flow in canines(151).
A potential limitation of this study is the canine animal model differs in comparison to
human hearts with regards to the increased number of collateral vessels. However, the
impact of this difference on the translation of these findings to humans is not currently
known. Further work using other large animal models such as pigs with reduced
collateral circulation may be needed.
It should be noted that although the study was performed using a hybrid PET/MRI
scanner, all of the techniques presented can also be implemented using PET/CT.

3.4 Conclusion
These early findings post cardiac irradiation echo the previous pre-clinical literature
using mice. However, the results from this study are presented in a large animal model
which more closely resembles the vessel architecture of humans than murine models.
Additionally, the findings are reported using a clinical imaging system and protocol that
can be easily modified for use in human studies. In light of these findings, we suggest the
use of this imaging approach for future human studies attempting to assess the clinical
efficacy of approaches to minimize cardiac exposure during left-sided breast irradiation.
Specifically, the efficacy of techniques aimed at reducing the risk of RIHD such as the
administration of anti-inflammatory medications (ex. ACE-inhibitors) may potentially be
assessed at much earlier time points through the use of
13

NH3 perfusion PET imaging.

18

F-FDG inflammation and/or
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Chapter 4

4

The utility of 18F-FDG and 13N-ammonia PET for
monitoring the progression of cardiac inflammation and
perfusion following focused cardiac irradiation in
canines

Chapter 4 hypothesis: A reduction in left ventricular perfusion and an enhancement in
inflammation is related to local radiation dose levels within the heart.
Cancer patients receiving radiotherapy for the treatment of thoracic malignancies such as
lung, breast, and esophageal are at risk of radiation-induced cardiovascular disease
(RICD). RICD is believed to be dose-dependent and can lead to the following:
pericarditis, valvular dysfunction, fibrosis, and/or coronary artery disease (32). Acute
pericarditis and valvular dysfunction are less prevalent today due to technological
advances in radiotherapy that have led to significant reductions in incidental cardiac
exposure. However, the more latent manifestation of RICD, coronary artery disease, is
still prevalent in both the “high-dose”(183) and “low-dose”(17) patient populations. A
recent clinical trial (183) (RTOG 0617) comparing radiation dose regimens for the
treatment of lung cancer, suggests that the benefit of high-dose deposition to lung
tumours may be outweighed by the risks associated with increased cardiac irradiation.
Furthermore, there is substantial interest in new treatment strategies aimed at reducing
cardiac toxicity following left-sided breast irradiation (17, 21, 43, 149, 184). Despite the
recognition of RICD as a significant hurdle in improving patient survival, our
understanding of the evolution of RICD is limited to preclinical studies in murine models
(49, 51, 185). In order to study RICD progression in humans, non-invasive means for
assessing cardiac toxicity with sufficient sensitivity to detect subtle changes before they
become clinically significant is needed.
Positron emission tomography (PET) imaging coupled with
18

13

N-ammonia (13NH3) and

F-fluorodeoxyglucose (FDG) are promising radiotracers for non-invasive, longitudinal

assessment of cardiac perfusion and inflammation respectively. The use of

13

NH3 PET

has been previously validated and widely considered the gold-standard in the assessment
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of cardiac perfusion non-invasively in humans (151, 186). The motivation to assess
myocardial perfusion comes from preclinical studies suggesting that radiation injury to
the microvasculature precedes RICD (52). Myocardial perfusion has been previously
studied in the context of RICD through the use of single photon emission computed
tomography (45, 47, 59, 99, 180, 187). SPECT studies suggest that perfusion changes are
expected in patients where at least 5% of the left ventricle is within the field (defined by
the 50% isodose line). However, to the best of our knowledge a direct correlation
between dose magnitude and changes in perfusion has not been previously reported. The
use of PET imaging has an advantage over SPECT due to the ability to provide absolute
quantification of myocardial perfusion using dynamic data acquisitions and tracer kinetic
modelling (188). Quantitative approaches to perfusion assessment have shown to be more
sensitive and more specific (189) in identifying myocardial perfusion abnormalities,
which is the typical pattern within the first decade after incidental cardiac irradiation
during radiotherapy. Additionally, due to the short half-life (~10mins),

13

NH3 may be

coupled with FDG PET in a single imaging session. FDG PET has been previously used
to assess cardiac inflammation in cardiac sarcoidosis (110) and following myocardial
infarction (111). Similar to perfusion abnormalities, preclinical studies have shown
evidence of an inflammatory response following cardiac irradiation and preceding RICD
(19). Although FDG cardiac PET imaging studies in the context of RICD exist, they are
limited to studies where radiation dose to the heart are more relevant to lung and
esophageal patients (41, 114–116, 190, 191). Extrapolating the lung and esophageal
radiotherapy findings to the breast cancer population is questionable considering the
significant differences in mean dose to the heart. Previous to Chapter 3 of this thesis and
to the best of our knowledge, FDG PET has not been used to assess cardiac inflammation
after exposure levels that are typically observed following left-sided breast radiotherapy.
The purpose of this study was to examine the utility of

13

NH3 and FDG PET in

monitoring the evolution of cardiac perfusion and inflammation following cardiac
external beam irradiation. Cardiac inflammation and perfusion imaging was repeated
over 12 months in a canine model before and following cardiac irradiation. Unlike
previous studies, cardiac irradiation was designed to mimic the typical heart exposure
observed after left-sided breast radiotherapy. In addition to non-invasive PET imaging, a
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preliminary histological analysis of the excised heart from a representative subject was
conducted 12 months following cardiac irradiation.

4.1 Materials and methods
4.1.1

Study design

The study design is outlined in Figure 4-1. Five bred-for –research female hounds (21-26
kg) underwent cardiac perfusion and inflammation PET imaging at baseline, and 3
months, 6 months, 12 months following focused cardiac external beam irradiation. At 12
months, the animals were sacrificed and the hearts were excised for histological staining.
The study was approved by the Animal Care Committee of the Western University
(Protocol 2014-005).

Figure 4-1: The study design and imaging time-points are outlined in panel A. The
PET/MRI imaging protocol performed each session is shown in panel B. In addition
to the PET/MRI imaging, the baseline imaging session included contrast and noncontrast enhanced computed tomography (CT) imaging for organ delineation and
radiation treatment planning, respectively. Abbrev. IV – intravenous; MRAC –
magnetic resonance attenuation correction.
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4.1.2

Imaging

The cardiac perfusion and inflammation PET imaging protocol (details in Figure 4-1,
panel B) was conducted on a hybrid PET-MR scanner (Biograph mMR; Siemens AG).
All radiation and imaging sessions were conducted using general anesthesia with
propofol for induction and 2% isoflurane to maintain a surgical level of anesthesia. A 2point Dixon pulse sequence was used for MRI-based attenuation correction. The 2-point
Dixon provides bulk substitution of attenuation coefficients for regions identified as fat
and water (124, 162). Good agreement between the 2-point Dixon method and CT-based
attenuation correction has been previously shown for cardiac PET imaging (162).
Cardiac perfusion was imaged using 13NH3 with list-mode PET acquisition reconstructed
into 16 dynamic frames (12x10s, 2x30s, 1x60s, 1x360s). PET data was reconstructed
using an ordered-subset expectation maximization algorithm (OSEM)(160) with 21
subsets, 3 iterations, 4-mm Gaussian smoothing filter, and 172x172x127 matrix size,
yielding a voxel size of 2.08x2.08x2.03 mm. Each animal was manually injected with a
bolus of ~5 MBq/Kg of 13NH3 radiotracer followed by a saline flush. In order to estimate
the myocardial perfusion reserve (MPR), each animal received two separate

13

NH3

injections, one at resting-state and another during pharmacological stress (following a 3
mg/min intravenous injection of adenosine over 10 minutes). Cardiac perfusion was
quantified in units of ml/min/g using a 1-compartment tracer kinetic model (107)
implemented using a semi-automatic software package, FlowQuant© (University of
Ottawa Heart Institute). Perfusion was quantified for each of 17 left ventricular segments
using the American Heart Association(AHA) model (153).
Cardiac inflammation was imaged using FDG PET after the suppression of the normal
physiological uptake of glucose by the myocardium. As described previously (111),
normal myocardial glucose uptake was suppressed through fasting and an intravenous
injection of unfractionated heparin (2000 IU) followed by a 20% lipid (Intralipid; Baxter
Health-care Corp.) infusion beginning 20 min prior to the injection of FDG. The mean
standard uptake value (SUV) was calculated from a respiratory gated, static PET
acquisition acquired 60 min after the injection of FDG. Similar to the perfusion analysis,
the SUV was quantified using the AHA 17 segment model.
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4.1.3

Radiation delivery

Each animal received a contrast enhanced and non-contrast enhanced fast helical
computed tomography scan (Discovery VCT; GE Healthcare) for organ delineation and
radiation delivery planning, respectively. Contours of the heart, left ventricle (LV), left
anterior descending artery (LAD), and left circumflex artery (LCX) were initially
generated on the contrast enhanced CT and then migrated to the registered non-contrast
enhanced CT. The non-contrast enhanced images and contours were transferred to a
clinical treatment planning system (Pinnacle3; Phillips Radiation Oncology Systems) for
radiation treatment planning. The treatment plan was designed to mimic the typical
cardiac exposure observed during left-sided breast radiotherapy. Dose-volume histogram
(DVH) metrics for the heart, LV, and LAD were obtained from 30 consecutive patients
previously treated for left-sided breast cancer. The 95% confidence intervals of the DVH
metrics were implemented as constraints in the development of the radiation plan for this
study. All animals received volumetric modulated arc therapy(154) (VMAT) plans
consisting of two, 180o, 6MV photon arcs that were deliberately focused onto myocardial
regions supplied by the LAD. In addition, dose to the LCX and the basal anterolateral
portion of the LV was minimized in order to compare cardiac function in irradiated and
less-irradiated myocardial segments. The dose distribution was calculated using the
adaptive convolve dose calculation algorithm (155, 157, 192).
In patients, radiation is typically delivered in multiple fractions. However, in this study a
biological equivalent dose (158) of the multi-fractionated treatment was delivered in a
single fraction. The multi-fractionated prescription (~30 Gy in 25 fraction prescribed to a
point within the LAD) was converted to a single fraction prescription using an α/β of 2.5
Gy (~9 Gy in 1 fraction) (159). All animals were irradiated using a TrueBeam linear
accelerator v1.6 (Varian Medical Systems, Palo Alto, USA). Radio-opaque markers,
wall-mounted lasers, and tattoos were used to aid in re-positioning the animal on the
accelerator. Image guidance through pre-treatment cone-beam CT and during treatment
fluoroscopy were used for additional setup verification.
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4.1.4

Histological analysis

A representative subject was selected for histological analysis. All animals were
euthanized using using an intravenous injection of potassium chloride. The isolated hearts
were rinsed with phosphate-buffered saline and fixed through aortic infusion of 10%
formalin and then fixed with formalin at room temperature for at least one week. The
fixed heart was embedded in 3.5% agar (Sigma A7002) and then sliced into 4.4 mm-thick
cross sections. The heart tissues were sampled according to standardized 17 segment
myocardial segmentation guideline for tomographic imaging as specified by the
American Heart Association (153). The segmented heart tissues were processed and
embedded in paraffin. Five-micron paraffin sections from each segment were stained
with hematoxylin and eosin for histology. Myocardial inflammation was assessed via
immunohistochemistry for CD45, a common leukocyte antigen, on tissue sections. CD45
was immunostained using a rabbit polyclonal CD45 antibody (ab10558, Abcam). Bound
antibodies were visualized using ABC reagent and diaminobenzidine (Vector
Laboratories). The bright-field images were acquired under Olympus BX-51 light
microscope. The abundance of CD45-immunoreactive cells was visually quantified in a
random high powered (40X) field at the anterior-septal region within the apex of the left
ventricle.

4.1.5

Data analysis

Mean values of myocardial perfusion, perfusion reserve, and inflammation were
compared to baseline values using a multivariate two-way repeated measures analysis of
variance (ANOVA). A bonferroni post hoc test was used to correct for multiple
comparisons. Perfusion and SUV values were grouped by anatomical region and also in
accordance with the typical canine coronary artery distribution (163). Each myocardial
segment was classified as being supplied by the LAD and/or the LCX artery. The
relationship between dose deposition and changes in cardiac perfusion/inflammation was
also assessed through Pearson’s product-moment correlation coefficient (R2). All
statistical tests were performed using SPSS 23 (IBM Corp.) and all values are reported as
mean ± standard error of the mean (SEM) unless otherwise indicated.
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4.2 Results
The blood plasma glucose levels, injected

13

NH3 activity, and injected FDG activity

during all imaging sessions is tabulated in Appendix F. All animals received cardiac
external beam irradiation that was deliberately focused onto the LAD. The spatial dose
distribution can be visualized for a representative subject in Figure 4-2. The mean
radiation dose delivered for the 5 animals to the heart, LV, LAD, and LCX was 1.7±0.1
Gy, 2.7±0.1 Gy, 5.5±0.3 Gy and 1.1± 0.2Gy, respectively. Delivered doses to the heart
and substructures for each individual subject are tabulated in Appendix F.
Cardiac inflammation was assessed through the comparison of cardiac FDG uptake at
baseline and following cardiac irradiation. The uptake of FDG in the LV myocardium
was increased in comparison to baseline for all animals. Figure 4-3, panel A shows the
increased FDG PET uptake in the heart, 12 months after cardiac irradiation for a
representative subject. The histological images following irradiation from the same
subject represented in the PET images is shown in Figure 4-3, panel B. Figure 4-3, panel
B show both the standard H and E staining as well as CD45 staining highlighting
persistent inflammatory cell activity at 12 months. Hematoxylin and eosin staining did
not identify any signs of fibrosis, or morphological damage to the LV wall. Irregular
endothelial cell morphology along the inner lumen of some arterioles and arteries were
also present.
Figure 4-4 shows a linear increase in SUV over the first 6 months. The increased uptake
of FDG relative to baseline was found to be statistically significant at all time points
following cardiac irradiation (p<0.01). The changes in FDG uptake compared to baseline
uptake were global and did not vary in response to the administered radiation dose with
no significant correlation found between regional dose and changes in FDG uptake
relative to baseline.
Changes in cardiac perfusion were monitored through

13

NH3 dynamic PET imaging

coupled with tracer kinetic modeling for absolute quantification of perfusion. An increase
in adenosine stress perfusion was observed throughout the entire LV at 3 months and 6
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months following cardiac irradiation (p<0.01). However, by 12 months the stress
perfusion had declined to near baseline levels.

Figure 4-2: Transverse, sagittal, and coronal contrast-enhanced CT slices (panel A)
showing the heart, left ventricle (LV), LAD, and LCX contours of a representative
subject. The radiation dose distribution is overlaid onto the anatomy in panel B.
Dose to the basal anterolateral portion of the LV and the LCX artery were
intentionally minimized (see panel B) in order to compare cardiac function in
irradiated vs less-irradiated segments.
Figure 4-5 and Figure 4-6 show similar changes in perfusion relative to baseline in both
areas of higher and lower radiation dose deposition. Similar to the FDG findings, no
significant correlation was found between regional dose and changes in perfusion relative
to baseline. A statistically significant increase in resting-state perfusion was observed at 6
and 12 months (p<0.01). Rest perfusion estimates in basal myocardial regions were
higher than in the apex of the left ventricle. Changes in myocardial perfusion reserve
relative to baseline were only observed at 3 months post irradiation (p<0.01).
Unfortunately, rest perfusion estimates at the 12 month time-point for subject 2 were not
obtained due to a technical issue during data acquisition.
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Figure 4-3: Panel A. Transverse and sagittal image slices of the 18F-FDG standard
uptake before and 12 months after cardiac irradiation for a representative subject
(subject 3). Panel B.

Histological slides from the left ventricular myocardium.

Hematoxylin and eosin staining and CD45 antigen immunohistochemistry staining
show cellular morphology and the presence of inflammatory cells respectively.
CD45 positively stained inflammatory cells (leukocytes) within the myocardium are
indicated by red arrows.
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Figure 4-4: The temporal progression of

18F-FDG

standard uptake within the left

ventricle myocardium. Uptake in panel A is grouped by myocardial regions
supplied by the left anterior descending (LAD) and/or the left circumflex (LCX).
Uptake in panel B is grouped by inferior, lateral, anterior, and septal myocardial
regions. Uptake in panel C is grouped by basal, middle (Mid) and apical (Apex)
myocardial regions. The estimated dose delivered is reported in the legend, error
bars indicate the standard error of the mean, and statistically significant difference
were observed between all time points (p<0.01).

Figure 4-5: The delivered radiation dose distribution (panel A) and adenosine stress
myocardial perfusion values at baseline and 3 months, 6 months, and 12 months
post cardiac irradiation (panel B). Dose and perfusion values are overlaid onto a
model of the left ventricle myocardium for a representative subject (subject 3).
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Figure 4-6: Changes in

13N-ammonia

myocardial resting-state perfusion (i),

adenosine induced stress perfusion (ii), and myocardial perfusion reserve (iii) pre
and post cardiac irradiation. Panels A. i), ii), and iii) are grouped by basal, middle
(Mid) and apical (apex) myocardial regions. Panels B. i), ii), and iii) are grouped by
inferior, lateral, anterior, and septal myocardial regions. The estimated dose
delivered is reported in the legend, error bars indicate the standard error of the
mean, and statistically significant difference are indicated by horizontal lines
spanning the comparison points as *p<0.05 and **p<0.01.

4.3 Discussion
The progressively increasing uptake of FDG in the myocardium is suspected to be due to
the infiltration of inflammatory cells in response to cardiac irradiation. This finding is
further supported though ex-vivo images of CD45 positively stained cells within the
myocardium. A similar pattern of inflammatory response following cardiac irradiation
has been previously shown in mice (48, 52, 182). Through the use of flow cytometry,
Sievert et al was able to show increases in endothelial cell surface markers related to
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inflammation and proliferation that remained elevated up to 20 weeks post
irradiation(52). The inflammatory response to cardiac irradiation has been previously
associated with structural damage to the myocardium and microcirculation (182);
however, hematoxylin and eosin staining of ex-vivo samples here did not result in
evidence of structural damage due to radiation. Since structural damage is usually
preceded by the inflammatory response, we suspect that this may have been observed in
our study had we extended the follow-up period beyond 12 months, even though
perfusion, in an absolute sense, was never compromised.

Our results parallel the

findings of preclinical studies in mice, although our study used a large animal model and
a clinical system capable of non-invasive imaging of human subjects. The large animal
model such as the canine provides a more representative model of the human cardiac
anatomy then mice (150). Further, the canine inflammatory response to myocardial
infarction has also been shown to be much closer to humans than the murine model,
where an accelerated pattern of inflammation is seen, much faster than observed in
patients.

Additionally, large animal models facilitate the translation of basic science

findings into clinical practice, specifically in the development of diagnostic imaging
protocols to be used in human studies. These findings support recent interest in the use
of ACE inhibitors for radioprotection of the heart (176) and the potential for FDG PET to
assess its efficacy. Although the typical use of ACE inhibitors is related to reducing
hypertension, studies have shown potential anti-inflammatory action capable of reducing
the reactive oxygen species created during tissue irradiation (193). However, additional
work is still needed to provide evidence of a link between cardiac inflammation and
future radiation induced cardiac toxicity. This link must be made in order to fully support
the use of FDG for assessing the efficacy of ACE inhibitors.
The

13

NH3 PET results show a transient increase in both rest and stress perfusion

following cardiac irradiation. To the best of our knowledge, no previous studies have
shown increases in quantitative myocardial perfusion following cardiac irradiation.
Previous clinical cardiac perfusion studies of left-sided breast cancer patients following
cardiac irradiation have mixed results and are limited to qualitative assessment of SPECT
images only. Zellars et al showed both regional increases and decreases in myocardial
perfusion scores 6 months after radiotherapy(43). Conversely, other studies have shown
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reductions in cardiac perfusion following radiotherapy in ~50% of left sided breast
cancer patients (45, 97, 100, 187). Chung et al did not observe any clinically significant
SPECT perfusion defects 6 months following left-sided breast radiotherapy(46).
Lawrence et al reported that the incidence of new perfusion defects 6, 12, 18, and 24
months after radiotherapy was 27%, 29%, 38%, and 42%, respectively(47). In our study,
two of the 5 subjects had 12 month stress perfusion estimates below baseline estimates,
consistent with the incidence rates reported by Lawrence et al(47). However, the regional
changes in perfusion in these two animals were not found to be correlated with the
regional dose. After aggregating the results from all subjects, we did not identify
statistically significant perfusion defects compared to baseline. The transient increase in
perfusion following irradiation shown here is supported by several murine studies that
have reported increases in endothelial cell proliferation, increases in microvascular
density, and increases in vascular permeability following cardiac irradiation, presumably
as an additional paired response associated with both the acute

and sub-acute

inflammatory response out to 6 months (181, 182).
Increased FDG uptake and myocardial perfusion were observed globally, affecting both
irradiated and “less” irradiated regions of the heart. This finding supports the conclusion
by Darby et al, suggesting that there may not be a dose threshold for which there is no
added risk of ischemic heart disease(17). In this study, approximately 8% and less than
1% of the LV wall received doses below 1 Gy and 0.5 Gy, respectively. We speculate
that focal changes in FDG uptake and or perfusion related to dose deposition would
require a more highly conformal delivery of radiation and a greater number of subjects
than presented here. However, this type of irradiation would be less-representative of the
left-sided breast cancer population.
The broad extrapolation of the findings presented from this study to the clinical
population is limited by the small number of animals assessed as well as other factors
outlined below. Stress perfusion and perfusion reserve values reported here are blunted in
comparison to literature values. This finding was consistent for all animals and present in
both pre and post cardiac irradiation scans. Suspicion that this may be due to the dosage
of adenosine injected for vasodilation prompted an additional experiment in two animals
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at 6 months with twice the dose of adenosine. The increased dose did not result in any
significant increases in stress perfusion either in absolute values or perfusion reserve.
Previous studies have also reported difficulties inducing a stress response using
adenosine infusion in the quantification of myocardial perfusion in canines (151). Lastly,
incidental cardiac irradiation following breast cancer radiotherapy is typically delivered
in multiple fractions; however, here the biological equivalent dose to the heart was
delivered in a single fraction. Literature support exists for the validity of applying the
linear quadratic model for single fraction deliveries (167); however this matter is still
debated(168, 169). A recent study focusing on stereotactic ablative radiotherapy has
suggested the use of a hybridization of the linear quadratic model and the multi-target
model to improve estimates of the biological equivalent dose for single fraction
deliveries(194). The estimated biological equivalent dose is also sensitive to uncertainty
in the accuracy of the alpha/beta reported by Gillete, et al(159). Fowler et al reported
changes in BED by ~5% per 1% change in alpha/beta(196). It should be noted that the
results from Chapter 2 suggest that uncertainty in the estimated mean dose to the LAD
used to calculate the BED greatly exceeds the reported uncertainty due inaccurate
estimates for the alpha/beta. Lastly, although the mean dose to the heart, LV, and LAD
are comparable to the exposures observed in the breast cancer population; the distribution
of the dose is different. In this study, a greater volume of the heart was exposed to low
doses of radiation (< 1 Gy) in comparison to what is observed in breast patients treated
with standard parallel opposed tangential beams.
Although we consistently observed increases in cardiac uptake of 18F-FDG as a result of
irradiation; a more complete histological analysis is needed to be certain that the increase
in

18

F-FDG post myocardial irradiation is due to cardiac inflammation. However, an

inflammatory response to cardiac irradiation is strongly supported by previous studies in
mice (48, 50, 51, 182). With regards to the validity of

18

F-FDG PET for assessing

inflammation, our group recently published a study using the same imaging protocol to
assess inflammation following myocardial infarction (111) with correlation of in vivo
FDG values with ex vivo measures of Indium labeled white blood cells. As indicated in
the methods section of the study by Prato et al, the myocardial suppression protocol used
to suppress myocardial glucose uptake was validated in a separate subset of 3 healthy
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canines(111). Given that the same protocol was implemented here by the same team and
using the same hardware, we are confident that the protocol was implemented correctly
and equally reliable. Additionally, these results were consistent for all subjects which
were imaged serially on separate days. Also, myocardial suppression was consistent and
achieved in all animals at baseline; this is qualitatively supported by the minimal contrast
between the LV blood pool and the myocardium on the baseline FDG images (see Figure
4-3) and quantitatively by the very low SUV values in the myocardium, well below the
values that are seen in images using glucose clamp techniques to augment myocardial
uptake of FDG (see Figure 1-8).
The cumulative dose to the heart from PET and CT imaging has been estimated using
previously reported values(197) in conjunction with the average injected tracer activity.
for this study to be ~0.2 mGy, 6.5 mGy, and ~6mGy for each

13

N-ammonia,

18

F-FDG,

and each CT scan respectively. Thus the total cumulative dose from all 6 imaging
sessions is approximately 1cGy which can be considered to have negligible impact on the
current findings since it accounts for less than 1% of mean dose delivered to the heart
from the medical LINAC.
We reiterate the statement from Chapter 3 that although the study was performed using a
hybrid PET/MRI scanner, all of the techniques presented can also be implemented using
PET/CT.

4.4 Conclusion
The results of this study have demonstrated that 13NH3 and FDG PET can be used for the
longitudinal assessment of myocardial perfusion and inflammation in association with
cardiac external beam irradiation. Canine cardiac irradiation was designed to mirror the
expected heart exposure associated with left-sided breast radiotherapy. In response to
cardiac irradiation, progressive increases in FDG uptake, a non-invasive means of
assessing inflammation, was observed and supported by ex-vivo histology in a single
representative subject. A transient increase in myocardial stress perfusion that returned to
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baseline levels (in 3 subjects) and below baseline levels (in 2 subjects) was observed.
These findings alone do not yet provide conclusive support for or against the future use
of

13

NH3 and/or FDG PET imaging for the longitudinal assessment of the efficacy of

treatment approaches previously proposed for reducing radiotherapy-related radiation
induced cardiac toxicity in humans. A further longitudinal study is needed to identify an
imaging parameter that is correlated with regional dose magnitudes and/or cardiac
outcomes.
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Chapter 5

5

Conclusions and Future Work

This chapter begins with a brief summary of the experiments, key results, and
conclusions from previous chapters of this thesis. The summary is followed by revisiting
the research questions and hypothesis that were initially proposed in the introduction (see
section 1.7). A discussion of proposed answers to those research questions and the level
of agreement between the initial hypothesis and the thesis results are provided. Lastly, we
motivate future clinical and pre-clinical research projects that can further advance the
findings of this work. Specifically, future projects that can 1) extend our fundamental
understanding of the pathophysiology of radiation-induced cardiac toxicity; and 2)
improve the clinical management/prevention of radiation-induced cardiac toxicity for
breast cancer patients subjected to radiation therapy.

5.1 Summary of Chapter 2
This chapter provided an assessment of the effects of respiratory-induced cardiac motion
on the ability to quantify the dose to the heart, left ventricle, and left anterior descending
(LAD) artery during standard breast cancer radiotherapy planning.
In breast cancer radiotherapy, the standard treatment planning approach uses a fast helical
CT scan that cannot accurately capture the motion of internal organs caused by breathing.
This is a concern for assessing dose to the heart since the anatomical position of the heart
is influenced by respiration. In other clinical cases where internal motion amplitude is
more pronounced (such as lung tumours) the fast helical CT is not appropriate. Rather, a
helical CT scan with a much smaller couch pitch is used to capture multiple slice images
over time. This technique is commonly referred to as a 4D-CT scan. The quasi-stalled
translation of the couch through the CT allows for multiple ‘snapshot’ images to be
acquired at the same axial slice position as a function of time. Additionally, during 4DCT imaging each axial image slice is tagged according to phase of the breathing cycle
during the acquisition. Since multiple images are obtained at each axial slice, it is
possible to retrospectively sort the images into multiple 3D volumes at multiple time
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points in the breathing cycle. Information regarding the breathing cycle used for sorting is
obtained from the motion of an external surrogate attached to the patient’s abdomen and
monitored using wall-mounted cameras. Using 4D-CT and a non-rigid image registration
algorithm, the planned radiation dose can then be warped in accordance to the motion of
the internal anatomy.
To assess the impact of respiratory motion on breast treatment planning, we compared the
standard fast helical CT to the 4D-CT scan techniques (with dose warping) for
calculating dose levels in of the heart, left ventricle, and LAD in 30 patients.
The results of this study showed minimal impact of respiratory motion on the mean dose
to the heart and left ventricle. However, substantial variation in dose due to respiratory
induced motion was observed for the left anterior descending artery (95% CI: ± 8.7 Gy).
We concluded that the fast helical CT could provide a good approximation for doses to
the heart and left ventricle; however, future clinical studies attempting to assess the
clinical impact of LAD irradiation should use 4D-CT derived dose estimates for
improved accuracy.
The study is unique in that it is the only published article (to the best of our knowledge)
assessing the dose uncertainty due to respiratory motion on cardiac substructures (left
ventricle and LAD) using the clinical imaging standard (fast helical CT). Previous studies
using 4D-CT have quantified dose to the heart as a whole(83, 84, 87, 88). The added
value of reporting the variations in left-ventricle and the LAD dose due to respiration is
supported in the literature(14). There is now ample mounting evidence that left-sided
breast cancer survivors experience a higher risk of radiation induced ischemic heart
disease, a disruption of the normal circulatory system of the heart(14, 17, 126). Thus, the
importance of dose estimates specifically to the left ventricle and LAD is warranted as
these are the main localized sites that include the micro and macro-circulatory systems of
the heart. Additionally, our study is the largest known study (30 patients) examining the
impact of respiration motion focused on the dose to heart substructures. The conclusions
drawn from Ding, et al (87) and Yue, et al (88) are based on a small sample of 6 and 7
left-sided breast cancer patients respectively.

95

The results from this study were also critical in the design of a clinically-relevant
radiation dose distribution for large animal (i.e. canine) studies presented in Chapter 3
and Chapter 4.

5.2 Summary of Chapter 3
This chapter provided early, in-vivo, non-invasive assessment of myocardial perfusion
and inflammation following focused cardiac irradiation in a canine model. Myocardial
perfusion and inflammation were assessed using

13

N-ammonia and

18

F-FDG positron

emission tomography imaging implemented on Canada’s first installation of hybrid PETMRI scanner. Using information from chapter 2, the delivered dose to the heart was
designed to resemble typical cardiac exposures of left-sided breast radiotherapy. The
radiation dose distribution was computed and delivered using clinical treatment planning
software (Pinnacle3, Phillips) and a state-of-the art medical linear accelerator (Truebeam,
Varian), respectively. Myocardial perfusion and inflammation scans were performed at
baseline, 1 week, and 4 weeks following cardiac irradiation. Absolute quantification of
perfusion was performed through tracer kinetic modeling. Similar to standard clinical
assessments, myocardial perfusion was assessed at both rest and during adenosineinduced vasodilation. To visualize myocardial inflammation using

18

F-FDG PET, image

data were acquired after the suppression of normal myocardial glucose metabolism to
avoid this confounding factor.
The results of this study showed an increase in both myocardial perfusion and
inflammation compared to baseline levels. Changes were observed at 1 week and
remained elevated up to 4 weeks. This functional response appeared to be global rather
than local, affecting both more intensely irradiated and less-irradiated myocardial
segments similarly. This finding is consistent with the observed lack of correlation
between local dose levels and changes in perfusion and 18F-FDG uptake.
To the best of our knowledge, the effects of cardiac irradiation at dose levels typically
observed in the left-sided breast cancer population have not been previously studied using
PET scans. The current findings are also supported by recently published results in a
murine model(52). The majority of pre-clinical studies on radiation induced cardiac
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toxicity have used murine models; however, here a large animal model of cardiac
exposures is presented instead and the scaling allowed delivery of dose distributions
comparable to human therapeutic exposures. The value added through the use of a large
animal model provides easier translation of our findings into clinical practice. The large
animal model offers a more representatively sized

heart than murine models(150).

Additionally, all previous nuclear imaging studies on the topic have used SPECT systems
with qualitative analysis. Here, using cardiac PET, changes were observed very early as
soon as 1 week post-radiation. This early observation is contrary to other imaging studies
where changes could not be detected until at least 6 months (typically 18 months) post
irradiation(45, 47).These findings are encouraging, however, future work is still needed
to assess whether or not these PET findings are precursors to clinical end-points such as
radiation-induced ischemia or if they are temporary effects of radiation that will resolve
naturally.

5.3 Summary of Chapter 4
The fourth chapter of the thesis is a continuation of the third chapter. The same imaging
techniques described in Chapter 3 were used to assess whether the early increases in
perfusion and 18F-FDG uptake are transient or persistent effects of cardiac irradiation. All
subjects were re-imaged at 3 months, 6 months, and 12 months using
18

13

N-ammonia and

F-FDG on a hybrid PET-MRI scanner. At 12 months the animals were euthanized and

their hearts were excised for ex-vivo histology. One sample subject was selected for
haematoxylin/eosin staining and CD45 immunohistochemistry to assess cellular
morphology and the presence of inflammatory cells, respectively. A significant number
of inflammatory cells were observed. However, histological analysis was preliminary as
it was only performed in a single animal. Further analysis is needed to confirm the
established presence and relative distribution of inflammatory cells within the left
ventricle of the myocardium.
The observed early increase in perfusion (seen in Chapter 3) relative to baseline was seen
to be maintained up to 6 months post cardiac irradiation. At 12 months, the myocardial
stress perfusion estimates returned to baseline in 3 subjects and dropped below baseline
in the remaining 2. A significant correlation could not be found between the magnitude of
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perfusion changes and local dose deposition.

To the best of our knowledge, early

increases in perfusion following cardiac irradiation have not been observed previously.
However, past myocardial perfusion studies following cardiac irradiation have been
limited to qualitative cardiac SPECT imaging at much later time points, 6 months post
irradiation(43, 45, 177, 198). This novel finding is supported by experimental studies in
mice showing increases in vascular permeability, increases in vascular endothelial cell
proliferation markers, and a transient increase in capillary density within 20 – 40 weeks
following cardiac irradiation (19, 125, 182).

These fundamental radiobiological

mechanisms support and may explain our PET imaging observations at early time points.
Statistically significant increases in

18

F-FDG myocardial uptake at 3 months, 6 months

and 12 months post irradiation were observed. Unlike perfusion, the uptake of

18

F-FDG

gradually increased with time and does not appear to be resolving to baseline levels. The
early increases in 18F-FDG myocardial uptake (seen in Chapter 3) relative to baseline do
not therefore appear to be temporary; this response is persistent in all animals over the
course of this 12 month study. This response to cardiac irradiation also appears to be
global. A significant correlation could not be found between the magnitude of

18

F-FDG

uptake changes and the local dose deposition. These findings are novel, but a more
complete histological analysis is still needed to assess whether the lack or correlation is
due to a true global inflammatory response or limitations in hardware sensitivity. To the
best of our knowledge, a non-invasive

18

F-FDG PET imaging assessment of

inflammation in which myocardial glucose metabolism is co-suppressed has not been
previously used following cardiac irradiation levels relevant to breast radiotherapy. An
inflammatory response to cardiac irradiation has been previously reported using ex-vivo
techniques in mice(33, 50, 52). Attempts to correlate regional dose to inflammation is not
currently possible in mice due to the small size of the heart. The findings from Chapter 4
are based on a much larger heart specimen and strongly support the clinical use of PET
for a more timely assessment of treatment strategies aimed at reducing radiation induced
ischemia.
The key results from Chapters 3 and 4 have been combined in Figure 5-1.
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Figure 5-1: The temporal progression of

18F-FDG

standard uptake (panel A),

13N-

ammonia rest perfusion (panel B), and stress perfusion (panel C) within the left
ventricle myocardium. Results are grouped by myocardial regions supplied by the
left anterior descending (LAD) and/or the left circumflex (LCX). The estimated dose
delivered is reported in the legend; error bars indicate the standard error of the
mean.

5.4 Conclusions
In Chapter 1, the goal of this thesis was motivated with the following previously
unanswered research question:
1. Does respiratory motion impact left-side breast cancer radiotherapy planning in
terms of the accuracy of estimating doses to the heart, left-ventricle, and left
anterior descending artery?
2. Can the effects of heart, left ventricle, and left anterior descending artery
irradiation on myocardial perfusion and inflammation be visualized using PET at
dose magnitudes comparable to modern left-sided breast radiotherapy?
3. Can the effects of cardiac irradiation be visualized using PET at earlier time
points in comparison to other previously used imaging modalities?
4. Is there a spatial relationship between the magnitude of dose and regional changes
in cardiac inflammation?
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5. Is there a spatial relationship between the magnitude of dose and regional changes
in cardiac perfusion?
6. Are specific regions within the heart, such as arteries, more sensitive to radiation
effects than others?
Question 1 was answered in Chapter 2 of this thesis. The answer to this question is “yes”
for the LAD and left ventricle but not for the heart. Using detailed 4D-CT scan data we
showed that respiratory motion had the most significant dosimetric impact on the LAD
(±8.7 Gy). The magnitude of the variations in dose to the heart (±0.5 Gy) and left
ventricle (±1.0 Gy) were much smaller. Additionally, the findings in the heart zone may
be considered negligible since they are on the same order of magnitude as previously
reported uncertainties due inter-observer variations in heart delineation(136). These
findings also agree with our first hypothesis: “A significant variation in dose across heart
structures is attributable to respiratory-induced motion during left-breast cancer
radiotherapy.”
Question 2 was answered in Chapters 3 and 4 of this thesis. The answer to this question
is “yes”. PET can measure the effects of cardiac irradiation on perfusion and
inflammation. We have shown statistically significant changes relative to baseline in
myocardial perfusion and 18F-FDG uptake (indicative of inflammation) using PET.
Question 3 was answered in Chapter 3 of this thesis. The answer to this question is also
“yes”. PET can visualize the effects of cardiac irradiation at earlier time points in
comparison to previously published more qualitative imaging studies using other
modalities such as SPECT. In Chapter 3 we measured a statistically significant increase
in both myocardial perfusion and
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F-FDG PET as early as 1 week post cardiac

irradiation. A caveat for this answer is that previous SPECT studies were performed in
breast cancer patients not a canine model. Although the canine model is routinely used
for cardiac studies, further study is needed to determine whether the temporal response to
radiation is different than what is observed in humans. For a definitive answer a humans
study using PET is proposed as future work
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Question 4 and Question 5 were answered in Chapters 3 and 4 of this thesis. The answer
to this question based solely on the results from this thesis is “no”. Both the perfusion
changes and

18

F-FDG uptake changes were not correlated with the spatial dose

distribution. The effects of cardiac irradiation appeared to be more global, affecting both
more irradiated and less irradiated segments similarly. A global response to focal cardiac
injury is not a unique finding to this study. Others have observed considerable
inflammatory

cell

recruitment

in

myocardium

remote

from

the

myocardial

infarction(199). Furthermore, there is published evidence in other organs of a remote
response in non-irradiated regions adjacent to irradiated regions, this is commonly
referred to as the “bystander effect”(200, 201). That being said, it is a possibility that a
correlation could be found given a larger sample size of animals; however, this is purely
speculative. In addition to a greater sample size, perhaps a steeper dose gradient would
yield a greater dose “spread” across myocardial regions for comparison. This may be
relevant if 18F-FDG PET may not have the sensitivity or specificity to detect potentially
subtle variations between myocardial regions irradiated by 9 Gy vs 1 Gy. Further study is
needed prior to completely ruling out the presence of a relationship between dose
magnitude and perfusion/inflammation changes.
In an attempt to answer Question 6, the dose distribution used in Chapters 3 and 4 was
designed such that cardiac function could be assessed in localized regions where 1) the
tissue and supplying artery were both focused with radiation; 2) only the tissue focused
but the supplying artery was minimally irradiated; and 3) the tissue and the supplying
artery were minimally irradiated. All three regions showed a similar response. Due to the
global response to cardiac irradiation, the radio-sensitivity of the left ventricular tissue
and the coronary arteries appear to be similar.
Our findings only partially agree with our second hypothesis: “A reduction in left
ventricular perfusion and an enhancement in inflammation are related to local radiation
dose levels within the heart.”
The observed increase in
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F-FDG was expected due to previous reports showing

increases in inflammation in response to cardiac irradiation(52).The increase in FDG is in
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agreement with our hypothesis; however, the result differs from the hypothesis in that it
was a systemic increase in FDG as opposed to one which is proportional to the dose
magnitude.
To the best of our knowledge the observed transient increase in perfusion has not been
previously observed. We suspected that cardiac irradiation would lead to a gradual
decline in perfusion. Declines in perfusion are hypothesized to be due to functional
damage to the microcirculation supported by previous SPECT perfusion studies(198).
Alternatively, the delivered cardiac doses in this study resulted in a reversed response by
the microcirculation. Although this was unanticipated, it may partly explain the
discrepancy with previously published SPECT perfusion studies. Perhaps the detection of
perfusion defects can only occur after the initial “survival response” has subsided. This
may explain the lesser incidence of cardiac perfusion defects at 6 months (27%) vs 24
months (42%) post radiotherapy(198). Lastly, the transient increase in perfusion followed
by a decrease at 12 months is supported by a recent pre-clinical study in mice showing a
transient increase in capillary density (+6-24%) at 20 weeks post radiation preceding a
decline at 60 weeks (182).

5.5 Future Work
5.5.1

Clinical PET assessment of radiation induced cardiac
toxicity following left-sided breast cancer radiotherapy

A natural continuation of the work presented in this thesis would be an extension to apply
the dose planning and imaging techniques to a sample of left sided breast cancer patients.
We propose a longitudinal study in humans comparing efficacy of alternatives to standard
parallel opposed radiotherapy treatment (alternatives were previously discussed in section
1.5). The use of baseline and 1 week/4 week post radiotherapy PET imaging is proposed
to assess cardiac inflammation in these patients. We hypothesize that patients showing
reduced inflammation on PET will be less susceptible to future radiation induced
ischemia. Unfortunately, this hypothesis cannot be assessed without long-term patient
follow-up (10-15 years post radiotherapy).
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Since it is well documented that inflammation often precedes tissue fibrosis(42),
inflammatory response in a cohort of patients could be counteracted through the use of
clinically approved anti-inflammatory medication (ie ACE inhibitors). Although ACE
inhibitors are primarily used to treat hypertension, they’ve also been shown to have antiinflammatory(202) and free radical scavenging properties(193). The use of ACE
inhibitors to reduce radiation-induced cardiac damage has shown promise in a recent
mouse study(176). Translation of these findings to humans would benefit significantly
from a non-invasive means of assessing local cardiac inflammation such as

18

F-FDG

PET.

5.5.2

Incorporating breathing induced cardiac motion information
in left-sided breast cancer radiotherapy planning to reduce
cardiac exposures

Many studies have shown that breathing-adapted radiotherapy ( respiratory gating or
breath-holds) can provide significant reductions in cardiac exposures (56). However,
these approaches can significantly increase the complexity and duration of planning and
treatment of patients. Treating all breast cancer patients with this approach will likely
reduce patient throughput and delay treatments. Furthermore, a recent study has shown
that for some patients, breathing-adapted radiotherapy may lead to worse cardiac function
than what is observed with the standard treatment approach(142). This problem motivates
the search for an approach to quickly stratify patients most likely to benefit from
breathing adapted radiotherapy.
Currently, two stratification criteria have been previously published: 1) stratification
based on the distance between the heart/LAD to a line segment spanning the sternum and
the mid-lateral edge of the body, referred to as mean heart depth(84), and 2) stratification
based on a dose-volume threshold (apply breath-holds if the standard treatment plan
results in more than 10 cm3 of the heart to be exposed to 25 Gy or more)(149). Although
conceptually simple to implement, the use of the mean heart depth for stratification has
not been widely accepted due to its poor correlation with the actual measured dose to the
heart and LAD (reported R2< 0.12) (84). The dose volume constraint proposed for
stratification by Wang, et al is derived from results from a previous study(47). Lawrence,
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et al, showed that the incidence of perfusion defects increased significantly (from 1020% to 50-60%) for patients with >5% of the left ventricle exposed to at least 25 Gy(47).
Unfortunately, implementing this dose-volume constraint for stratification requires a
complete radiotherapy treatment plan to be created prior to making the decision. Unless
centres can automate the task of creating breast radiotherapy plans, this method may
significantly increase the treatment planning workload and lead to delays in patient
treatments.
A future study where each patient’s breathing-induced cardiac motion is characterized is
likely needed to establish better patient selection guidelines. For example, the impact of
breathing motion is routinely characterized in lung cancer treatment planning through the
use of 4D-CT. In lung cancer radiotherapy planning, the motion derived from the 4D-CT
is used to create an internal target volume that encompasses the full range of tumour
motion. We have shown in Chapter 2 that 4D-CT can also similarly be used to
characterize the dosimetric impact of heart, left ventricle, and LAD motion. The ability to
characterize the motion of the heart and LAD, can potentially lead to patient specific
motion margins for these organs as well. Future studies may choose to investigate the
role of cardiac motion margins created for avoiding the heart, left ventricle, and LAD at
all possible phases of the breathing cycle. Without further investigation, the fast helical
CT will likely continue being the clinical standard for breast radiotherapy planning and
the effects of breathing on heart dose will continue to be ignored until 4D CT is
implemented routinely.

5.5.3

Potential improvements in radiation induced cardiac toxicity
models

Pre-clinical research is still needed to help us better understand the underlying pathophysiology of radiation induced cardiac toxicity. The relationship between dose
magnitude and cardiac injury is still not well understood and raises questions about local
and global response outside the irradiated zone. Previous proposals that cite a 7.4%
increase in the rate of a major coronary event per 1 Gy dose to the heart may not be
relevant today since this relationship was derived from obsolete breast cancer treatment
techniques between the year 1958 and 2001(17). In addition, today’s patients receive
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adjuvant therapy, combining radiation with new chemotherapy agents not previously
used until the early 2000’s. The relevance of this to radiation-induced cardiac toxicity is
motivated by evidence linking chemotherapy with severe cardiac disorders(203–205).
Anthracyclines (FDA approval in early 1970’s) and trastuzumab (FDA approval in late
1990’s) are two breast cancer chemotherapy agents that are commonly used and have
been shown to negatively impact cardiac function. The effects of anthracyclines on
cardiac function are well documented(206–208). Swain, et al, reviewed the literature and
concluded that the cumulative percentage of patients with anthracycline-related
congestive heart failure was between 5% - 26% (206). Anthracyclines have been shown
to cause a buildup of reactive oxygen species that directly damage mitochondrial DNA
within cardiomyocytes inducing cell death(209). This effect is similar to radiationinduced oxygen effects and may be compounded by chemotherapy activation.
Anthracyclines directly damage cardiomyocytes, however, trastuzumab is believed to
indirectly impact the cells through the disruption of the repair process(210). Furthermore,
it is believed that these cardio toxic effects are even greater for patients with significant
cardiac irradiation(211).
In light of this, future animal models attempting to study the relationship between cardiac
toxicity and radiation should also include anthracyclines and trastuzumab. Here, we have
shown the utility of PET for assessing cardiac response to radiation alone, however future
PET studies should include the combined effects of chemotherapy and radiation.

5.5.4

Cardiac radio-sensitivity and setting clinical guidelines for
“safe” exposure levels

It has been previously hypothesized that the radio-sensitivity of the heart is
heterogeneous, meaning that some parts of the heart respond differently to radiation
exposure than other regions. This heterogeneity in sensitivity has been observed in
preclinical studies comparing the effects of coronary artery irradiation versus left
ventricle irradiation(15, 18). Coronary artery irradiation has been shown to cause an
acceleration of the formation of plaques that are prone to rupture(33). The left ventricle
tissue is highly vascularised and irradiation of this structure leads to significant decline in
the local functional capillaries(182). Both these effects are not mutually exclusive and
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can lead to myocardial ischemia and infarction. Safe dose limits for each of these specific
cardiac substructures are not yet known. In light of this, the current guidelines based on a
single dose value (i.e. mean heart dose) may be a gross oversimplification.
Both dose magnitude and irradiated volume need to be considered when setting dose
tolerance levels for organs. For the heart it is not known whether a low dose delivered to
a large volume is less harmful than a high dose to a small volume.

It has been

hypothesized that the functional integrity of the coronary arteries is analogous to a chain.
In other words, these arteries may constitute a radiobiological “serial organ” and the
functionality of all of the subunits that make up the artery must be maintained. The
radiation tolerance of serial organs such as the spinal cord depends on the magnitude of
local dose delivered to a sub-unit than the total irradiated volume. Conversely, parallel
organs such as the lungs and kidneys have a considerable functional reserve capacity;
meaning they can still function normally even when small fraction of the organ is
damaged. The microcirculation of the heart is housed in the left ventricles and has
significant functional reserve capacity, supporting the hypotheses that unlike the artery it
will behave as a parallel organ. Setting exposure guideline for the heart is therefore
complicated because it is functionally dependent on both the major coronary arteries
(serial organs) and the left ventricular tissue (parallel organ).
Future studies attempting to assess exposure guidelines for cardiac sub-units such as the
coronary arteries and left ventricles should be performed in large animal models not
mice. With the large animal models the heart is large enough to allow for more focused
irradiation of the arteries and/or left ventricular tissue. Such a study can potentially lead
to separate dose limits for the arteries and the left ventricle replacing or augmenting the
current use of the total mean heart dose. In summary, we continue to propose that a large
animal model should be used to mimic clinically-relevant dose levels and dose
distributions giving opportunity to distinguish serial and parallel responses.
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5.5.5

Hybrid PET-MRI imaging of radiation induced cardiac
toxicity

Although this thesis used a hybrid PET-MRI system to assess cardiac function following
radiation exposure, only PET findings were reported and used in our studies. As
previously discussed (sections 1.6.5), the MRI compliments the PET system by adding
both additional functional imaging options and anatomical context. Also, since PET-MRI
systems can acquire images simultaneously, the imaging protocol implemented in
Chapter 3 and Chapter 4 can be significantly reduced by assessing perfusion using
dynamic contrast enhanced MRI while simultaneously assessing inflammation with

18

F-

FDG PET. Decreasing the imaging session duration is important for maintaining
compliance when attempting to translate animal research to humans. Furthermore the use
of MRI is more suitable for longitudinal human studies due to the reduction in radiation
doses to the patient compared with PET imaging alone. Lastly, in addition to assessing
perfusion with MRI, the system can determine the potential presence of radiation-induced
edema, wall motion abnormalities, and fibrosis. To the best of our knowledge in-vivo
assessment of radiation induced cardiac edema and fibrosis has not been fully quantified
using MRI. Edema and fibrosis are two additional sub-clinical end points that may be
used for assessing radiation induced cardiac toxicity mitigation strategies in humans.
It is hoped that the imaging and dosimetric findings reported in this thesis will assist in
developing novel cardiac toxicity reduction strategies that will enhance complication-free
survival of breast cancer patients subjected to the benefits of effective adaptive
radiotherapy.
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Appendix B: Worked general solution to equation 1-1

𝑑𝐶𝑡𝑖𝑠𝑠𝑢𝑒 (𝑡)
= 𝜌𝐾1 𝐶𝑏𝑙𝑜𝑜𝑑 (𝑡) − 𝐾2 𝐶𝑡𝑖𝑠𝑠𝑢𝑒 (𝑡)
𝑑𝑡

1-1

begin by taking the Laplace transform of both sides of equation 1-1
𝐿{

𝑑𝐶𝑡𝑖𝑠𝑠𝑢𝑒 (𝑡)
} = 𝐿{𝜌𝐾1 𝐶𝑏𝑙𝑜𝑜𝑑 (𝑡) − 𝐾2 𝐶𝑡𝑖𝑠𝑠𝑢𝑒 (𝑡)}
𝑑𝑡

in the Laplace domain we have the following equation
̅
̅
̅
(𝑡) − 𝐶𝑡𝑖𝑠𝑠𝑢𝑒 (0) = 𝜌𝐾1 𝐶𝑏𝑙𝑜𝑜𝑑
(𝑡) − 𝐾2 𝐶𝑡𝑖𝑠𝑠𝑢𝑒
𝑠𝐶𝑡𝑖𝑠𝑠𝑢𝑒
(𝑡)

A-1

̅
(𝑡) 𝑎𝑛𝑑 𝐶𝑡𝑖𝑠𝑠𝑢𝑒 (0) are the Laplace transform of 𝐶𝑡𝑖𝑠𝑠𝑢𝑒 and the initial
where 𝐶𝑡𝑖𝑠𝑠𝑢𝑒
condition in the time domain respectively. Since the initial condition is equal to zero we
̅
(𝑡)
can rearrange equation A-1 to solve for 𝐶𝑡𝑖𝑠𝑠𝑢𝑒
̅
(𝑡) =
𝐶𝑡𝑖𝑠𝑠𝑢𝑒

𝜌𝐾1 𝐶̅𝑏𝑙𝑜𝑜𝑑 (𝑡)
𝑠+ 𝑘2

̅
̅
(𝑡) = 𝜌𝐾1 𝐶𝑏𝑙𝑜𝑜𝑑
(𝑡) 1
𝐶𝑡𝑖𝑠𝑠𝑢𝑒
𝑠+ 𝑘

2

The following equation is obtained by taking the inverse Laplace transform of both
sides. Also, recall that multiplication in the Laplace domain is convolution in the time
domain.
̅
̅
(𝑡)} = 𝐿−1 {𝜌𝐾1 𝐶𝑏𝑙𝑜𝑜𝑑
(𝑡)} ⊗ 𝐿−1 { 1 }
𝐿−1 {𝐶𝑡𝑖𝑠𝑠𝑢𝑒
𝑠+ 𝑘
2

𝐶𝑡𝑖𝑠𝑠𝑢𝑒 (𝑡) = 𝜌𝐾1 𝐶𝑏𝑙𝑜𝑜𝑑 (𝑡) ⊗ 𝑒 −𝐾2 𝑡
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Appendix C: Summary of patient treatment characteristics
Treatment Description

Prescribed Radiation Dose

Number of
Patients

Whole Breast POP
Standard

50 Gy in 25

7

42.5 Gy in 16

6

50 Gy in 25; 10 Gy in 5

3

42.5 Gy in 16; 10 Gy in 5

4

+ SCLAV

50 Gy in 25

2

+ Boost; + SCLAV

50 Gy in 25; 10 Gy in 5

1

+ IMC

42.5 Gy in 16

1

+IMC; +SCLAV

50 Gy in 25

1

+SCLAV

50 Gy in 25

3

+SCLAV; +IMC

50 Gy in 25

2

+ Boost

Chest Wall POP

Abbreviations: POP: tangential parallel opposed photon beams; SCLAV: supraclavicular
irradiation; IMC: internal mammary chain irradiation (wide tangential parallel opposed photon
beams); *all delivered using photons ( 6MV or 6MV & 18 MV Fields)
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Appendix D: Animal Ethics Approval
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Appendix E: Summary of multi-fractionated and BED corrected single fraction
radiation dose constraints to the heart obtained from clinical patient data.
Standard
Multi-Fractionated
patient derived data

Biological Equivalent
Dose (BED)

Single Fraction Delivery
Dose Constraints

Mean

95% CI

mean

95% CI

mean

95% CI

2.3

[1.7, 3.0]

2.4

[1.7, 3.1]

1.5

[1.2, 1.8]

18.4

[9.2, 27.6]

-

-

-

-

mean dose (Gy)

3.1

[2.2, 4.2]

3.4

[2.3, 4.5]

1.2

[1.4, 2.3]

3

6.5

[2.6,10.5]

-

-

-

-

mean dose (Gy)

11.9

[8.6, 15.3]

14.2

[9.8, 19.0]

4.8

[3.8, 5.8]

D0.4 (Gy)

28.8

[17.5, 30.2]

42.1

[22.4, 44.8]

9.1

[6.3, 9.4]

Heart
mean dose (Gy)
3

V50 (cm )
Left ventricle
V50 (cm )
LAD

Abbreviations: CI: confidence interval; V50: volume of organ receiving at least 50% of the prescribed
dose; D0.4: maximal dose to 0.4 cm3 of the organ; LAD: left anterior descending artery. * α/β ratio used
for BED calculation was 2.5 Gy (Gillette S, et al. Radiother. Oncol. 1992;23:41–52)
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Appendix F: Summary of experimental details and cardiac dose distribution
injected radiotracer
activity
(MBq)

PGL
(mmol/L)
13

Nstress

13

Nrest

18

FDG

Subject 1
baseline
1 week
4 week

6.4
5.6
4.4

107
105
100

106
102
104

100
101
96

3 months
6 months
12 months

4.7
5.3
6.2

95
108
85

51
106
104

94
108
103

baseline
1 week
4 week

4.8
4.6
3.5

104
97
106

104
96
105

110
97
98

3 months
6 months
12 months

5.6
4.5
5.8

103
116
91

106
74
110

91
114
97

baseline
1 week
4 week

6.2
6.2
4.9

101
100
90

106
101
102

96
103
114

3 months
6 months
12 months

4.7
4.7
5.9

85
143
100

89
108
100

98
103
110

baseline
1 week
4 week

5.2
5.2
4.9

102
101
105

112
106
101

94
110
100

3 months
6 months
12 months

4.5
4.6
5.2

90
84
111

103
105
95

109
112
90

6.3
5.9
5.6
4.8
5.8
6.1

95
98
108
103
100
109

114
88
106
97
107
108

111
100
105
107
107
104

5.3±0.1

101±2.3

100±2.5

103±1.4

Subject 2

Subject 3

Subject 4

Subject 5
baseline
1 week
4 week
3 months
6 months
12 months

mean

cardiac dose distribution
mean dose (Gy)
Heart
1.9

LV
3.0

LAD
6.8

LCX
0.8

1.6

2.5

4.7

0.9

1.5

2.4

5.7

1.2

1.8

2.6

5.6

1.7

1.9

2.9

4.7

0.8

1.7±0.1

2.7±0.1

5.5±0.3

1.1±0.2

Abbreviations: PGL: plasma glucose level; 13Nstress: ammonia injection during pharmacological stress perfusion; 13Nrest: ammonia injection
during rest perfusion; LV: left ventricle; LAD: left anterior descending artery; LCX: left circumflex artery. All data presented as mean ±
standard error of mean. Since the radioactive decay follows a Poisson distribution, the expected standard deviation in the individual tracer
activities is equal to the square root of the measured activity.
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